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1. INTRODUCTION
In a country like India because of ever increasing population, the demand for health
care  services is also increasing.  With changing lifestyles and so-called “fast culture” good
health is  almost deprived. In this tremendous speed of life, the health, as defined by World
Health  Organization (WHO) is  difficult  to attain.  With the up gradation of life  style,  the
concepts  and  severity  of  illness,  diseases  and  disorders  are  also  changing.  The  major
challenge faced by healthcare professionals in this view is that of gradation of the available
drug delivery systems. The ultimate goal of any drug delivery system is effective disease/
disorder  management,  minimum  side  effects  and  greater  patient  compliance  in  the  cost
effective manner. The drug therapeutic indices could be maximized while indices of adverse
reactions or side effects could be minimized by regulating the drug release in body in a well-
defined  controlled  manner.  This  would  eliminate  the  haphazard  and  uncontrolled  blood
plasma profiles of drugs usually associated with conventional dosage forms1.
There  are  numbers  of  potential  limitations  associated  with  conventional  per  oral  dosage
forms2, they are as follows:
 1.The concentration  of  drug  in  plasma  and hence  at  the  site  of  action,  fluctuates  over
successive dosing intervals even at the steady state condition .Therefore it is not possible to
maintain constant therapeutic concentration of drug at the site of action. 
2. The fluctuations of steady state concentration drug in plasma can subject the patient either
to under medication or over medication. For drugs with short biological half-lives (<2 hrs),
frequent doses would be required to maintain steady state plasma concentration.
These limitations, gives rise to the need for designing new drug delivery systems, which will
eliminate or reduce the cyclical plasma concentrations seen after frequent administration of
conventional drug delivery systems.  The overall action of a drug molecule is dependent on its
inherent therapeutic activity and the efficiency with which it is delivered to the site of action.
An increasing appreciation of the latter has led to the evolution and development of novel
drug  delivery  systems  (NDDS),  aimed  at  performance  enhancement  of  potential  drug
molecules.   A  variety  of  approaches  has  been  used  to  provide  predictable,  precise  and
reproducible pattern of controlled release or even site-specific delivery of drugs.
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These  approaches  have  provided  a  valuable  tool  to  the  pharmaceutical  industry  for
enhancing the efficiency of delivery of a number of drug molecules.  This in turn has
offered enhanced commercial gains and extension of life cycle of products.
         Various designations are used to describe the per oral NDD systems such as delayed
release  systems,  repeat  action,  prolonged  release,  sustained  release,  extended  release,
controlled release, and modified release systems.
Per oral controlled release (CR) technology has following objectives:
• Reduction in frequency of administration and improved patient compliance
• Reduction in side-effect profiles of drug by maintaining blood levels within the
therapeutic range.
• Increased safety and efficacy of drug due to reduced fluctuations in blood levels.
• Maintenance of therapeutic drug concentration even during the night
        Among these the reduction in frequency of drug administration has been the most sought
strategy in designing various per oral CR dosage forms. It is always advantageous to have
good insight of biopharmaceutical characteristics of the drug molecule, and its interplay with
various components of the biological system.
        The ultimate goal  of a drug delivery device,  whether  traditional  or nove,  should
therefore  be to attain and maintain drug concentrations within the therapeutic window or
close  to  the  average  concentration,  for  the  requisite  duration,  with  minimum fluctuation.
Some of  the parameters  likely to  have an important  forbearing  on designing  of  oral  CR
formulations are given below:
Rational of controlled drug delivery system8,9
              The basic rational for sustained/controlled drug delivery systems is to alter the
pharmacokinetics  and  Pharmacodynamics  of  pharmacologically  active  moieties  by  using
novel drug delivery systems or by modifying the molecular structure and or physiological
parameter inherent in a selected route of administration.
1. Reduction in fluctuation of drug blood levels about the mean.
2. Reduce the dosage frequency.
3. To improve patients compliance.
4. To ensure safety and improve efficacy of drugs.
2
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5. More consistent and prolonged therapeutic effect.
6. Decreased incidence and intensity of adverse effects and toxicity.
7. Better drug utilization.
Basic gastrointestinal tract physiology
Fig-1 Anatomy of stomach
To comprehend the consideration taken in the design of the GRDDS and to evaluation their
performance, the relevant anatomy (shown in above diagram) and physiology of the GI tract
must be fully understood. The GI tract is essentially a tube about 9 m long that run from
mouth to the anus and includes throat (pharynx), oesophagus, stomach, small intestine, and
large intestine.  The wall of GI tract has the same general structure through most of its length
from the oesophagus to the anus, with some local variation for each region.
 The stomach is a j-shaped dilated portion of the alimentary tract situated in the epigastric,
umbilical and left hypochondriac region of the abdominal cavity. Its size varies according to
the amount distention: up to 1500 ml following a meal, after food has emptied, a `collapsed’
state is obtained with a resting volume of only 25-50 ml.  The stomach is composed of the
following parts: fundus, above the opening of the oesophagus into the stomach; body, the
central part; and antrum.  The pylorus is an anatomical sphincter situated between the most
terminal antrum and the duodenum.  The fundus and body store food temporarily,  secrete
digestive juice and propels chime, a milky mixture of food with gastric juice to the antrum.
The antrum grinds and triturates food particles and regulates the secretion of hydrochloric
acid as well as emptying of food.
3
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          Fasting gastric pH is specially steady and approximate 2, but there are short periods of
7 ± 6 min characterized by higher values.  Food buffers and neutralizes gastric acid, the pH
rapidly falls back below 5 and then gradually decline to fasting state values over a period of
few hrs.
           The pyloric sphincter has a diameter of 12.8 ± 7 mm in humans.  The duodenal pH is
6.1; and its transit time is relatively short, less than 1 min.  The small intestine has a large
surface area,  which is comparable to the area of basketball,  463 m2   The pH of the small
intestine is 6-7 and its transit time is 3 ± 1 hrs, is relatively constant and is unaffected by
food.   The  colon  has  some  absorption  properties  of  water  and  ions,  certain  drug  and
especially peptide molecule are also absorbed.
Physiological factors important for oral controlled drug delivery systems5
1. Gastric emptying
The process of gastric emptying occurs during both fasted stated and fed state however,
the pattern of  motility differs  markedly in these two states.   In  the fasted state,  it  is
characterized  by  an  inter  digestive  series  of  electrical  events,  which  propagate  both
through stomach as well as small intestine every 2-3 hrs.  This activity is called as inter
digestive myoelectric complex (MMC), and is often divided into four consecutive phases.
Phase I:  It is a quiescent period lasting from 40-60 min. with rare contractions. 
Phase II:  It  is a period of similar duration consisting of intermittent  action potentials
gradually increases an intensity and frequency as phase progresses.
Phase III: It is short period of intense, large regular contractions lasting from 4-6 min. as
it serves to sweep undigested materials out of stomach and down in small intestine, it is
termed as `housekeeper waves’. As the phase III of one cycle reaches the distal part of
small intestine, the phase III of next cycle begins in duodenum.
Phase IV: It is brief transitional phase that occurs between phase III and phase I of two
consecutive cycles.  In the fed state, the gastric emptying rate is slowed since the onset of
MMC is delayed.  In other words, feeding results in a lag time prior to onset of gastric
emptying.
4
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 Factors affecting gastric emptying time6
1. Volume:  The resting volume of stomach is about 25-52ml. This volume is important
for dissolution of dosage forms. As the volume is large, emptying is faster. Gastric emptying
of small volumes like 100 ml or less is governed by Migrating Myoelectric Complex (MMC)
cycle whereas large volumes of liquids like 200ml or more are emptied out immediately after
administration.  Fluids  at  body  temperature  leave  the  stomach  more  rapidly  than  either
warmer or colder fluids.
2. Hormonal effects:  Stress conditions increases gastric emptying rate whereas depression
slows down gastric emptying time. Generally females have slower gastric emptying rate than
males. Age and obesity also affect gastric emptying.
3. Presence of  food:   Gastric emptying time differs  in fasted state and in fed state.  The
calorific value of food affects the gastric emptying time.
4. Gastric secretions:  Acids, pepsin, gastrin, mucus and other enzymes are the secretions of
stomach. Normal adults produce a basal secretion up to 60ml with approximately 4mm mole
of hydrogen ions every hrs.
Factors affecting gastric residence time of dosage forms are 
Size and Shape of dosage forms
Studies have revealed that gastric emptying of a dosage form in the fed state can also be
influenced by its size. Small-Size tablets leave the stomach during the digestive phase while
the large size tablets are emptied during the housekeeping waves. 
Density 
Dosage  forms  having  a  density  lower  than  that  of  gastric  fluid  experience  floating
behaviour and hence gastric retention. A density of < 1.0gm/cm is required to exhibit floating
property. However, the floating tendency of the dosage form usually decreases as a function
of time, as the dosage form gets immersed into the fluid, as a result of the development of
hydrodynamic equilibrium. 
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Concomitant administration of drugs 
Concomitant administration of anti-cholinergic drugs,  prokinetic  agents  affects  the gastric
residence time of dosage forms. 
Regional variability in intestinal absorption concept of absorption window9,10
The  gastrointestinal  tract  (GIT)  offers  a  varied  environment  capable  of  affecting  the
absorption of per orally administered drugs.  These changes are contributed by anatomical
features, physiological phenomenon, and nature of  gastrointestinal milieu This can lead to
the variations in intestinal permeability of drug molecules, resulting in the phenomenon of
‘absorption window’  wherein  the drug is  preferentially  absorbed  only from a particular
region of the GIT. Not all drugs candidates get uniformly absorbed throughout the GI tract.
Drugs exhibiting absorption from only a particular region of GI tract or showing difference in
absorption from various regions of GI tract are said to have regional variability in intestinal
absorption. Such drugs show ‘absorption window’ which signifies the region of GI tract from
where absorption primarily occurs. The below diagram gives the various sites in GIT from
where the drug absorption takes place.
Fig-2 Sites in G.I tract for absorption of drug from conventional dosage from stomach, 
duodenum and jejunum.
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This absorption window is observed due to following factors6,9
1. Physicochemical factors
a. pH dependent solubility
b. pH dependent stability
c. Degradation due to enzymes
2. Physiological factors
a. Mechanism of absorption
b. Degradation by intestinal micro flora
1. Physico – chemical  factors
pH-dependent solubility and stability: A drug experience a PH range of 1-8 across the
GIT, and needs to be in solubilised and stable form to successfully cross the biological
membranes. Most of the drugs are passively absorbed; in their un-ionized form and the
extent of ionization at different pH in different regions of GIT can significant alter the
absorption  profile.  pH dependent  solubility,  stability  and  ionization  by  changing  the
physical  properties  of  the  drug in  different  portions  of  the GIT,  can lead  to  regional
variability in absorption of drugs.
2. Physiological factors:
An orally administered drug experiences certain physiological  phenomenon which can
contribute to absorption window. 
Mechanism of absorption: Per orally administered drugs are absorbed both by passive
diffusion as well as by non-passive means of absorption. Drugs absorbed by active and
facilitated transport mechanisms show higher regional specificity due to the prevalence of
these mechanisms only in a particular region of GIT. 
Metabolic enzymes:  Presence of certain enzymes in a particular region of GIT can also
lead to regional variability in absorption of drugs that are substrates to those enzymes
intestinal metabolic enzymes (majorly,  phase one metabolizers),  like cytochrome p450
(eg, CYP3A), are abundantly present in the intestinal epithelium. 
First-pass  metabolism: Hepatic  first-pass  metabolism  is  another  major  contributory
factor in reducing the bioavailability of orally administered drugs. A major portion of
intestinally absorbed drugs is taken up by the portal veins to liver, a potential site of drug
7
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metabolism. On the contrary, hepatic first-pass metabolism is of considerable interest in
regard of drugs whose therapeutic actions is dependent on their hepatic metabolism. It is a
well-accepted fact that it is difficult to predict the real in vivo time of release with solid,
oral controlled release dosage forms. Thus drug absorption in the gastrointestinal (GI)
tract may be very short and highly variable in certain circumstances.  
 “The aim of oral controlled release dosage form is not just to prolong the delivery of
drugs for more than 12hrs but to prolong the residence time in absorption region for
desired period of time.” 
          One of the most feasible approaches for achieving a prolonged and predictable drug
delivery profile  in the GI tract  is  to control  the gastric  residence  time (GRT).Dosage
forms with a It is evident from the recent scientific and patent literature that an prolonged
GRT, i.e Gastro retentive dosage forms (GRDFs) will provide us with new and important
therapeutic options. GRDF’s extend significantly the period of time over which the drugs
may be released. Thus, they not only prolong dosing intervals, but also increase patient
compliance over the existing controlled release dosage forms.
Applications of GRDDDS9,10
 1.     Delivery of sparingly soluble and insoluble drugs
Especially  effective  in  delivery  of  sparingly  soluble  and  insoluble  drugs,  as  the
solubility of a drug decreases, the time available for drug dissolution becomes less adequate
and thus the transit time becomes a significant factor affecting drug absorption. To address
this, oral administration of sparingly soluble drugs is carried out frequently,  often several
times per day.
2. Pharmacotherapy of the stomach
GRDFs  greatly  improve  the  pharmacotherapy  of  the  stomach  through  local  drug
release, leading to high drug concentrations at the gastric mucosa (eradication Helicobacter
pylori from the sub mucosal tissue of the stomach), making it possible to treat stomach and
duodenal ulcers gastritis and oesophagitis, reduce the risk gastric carcinoma and administer
non-systemic controlled release antacid formulations (calcium carbonate).
8
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3. Delivery of drugs with absorption window
GRDFs can be used as carriers for drugs with so-called absorption windows these
substances,  for  example  antiviral,  antifungal  and  antibiotic  agents  (sulphonamides,
quinolones, penicillin, cephalosporins, amino glycosides and tetracyclines, etc.) are taken up
only form very specific sites of the GI mucosa. In addition, by continually supplying the drug
to its most efficient site of absorption, the dosage forms allow foe more effective oral use of
peptide  and  protein  drugs  such  as  calcitonin,  erythropoietin,  vasopressin,  insulin,  low-
molecular-weight  heparin,  protease  inhibitors  and  lutenising  hormone-releasing  hormone
analogues.
Formulation Approaches for Gastric Retentive Drug Delivery Systems (GRDDS)15,16
Over last three decades, various approaches have been pursued to increase the retention of
an oral dosage form in the stomach, which include
• Floating systems (low density approach),
• Swelling and expanding systems,
• Bioadhesive systems,
• Modified shape systems,
• High density systems, and
• Delayed release gastric emptying devices
• Super porous hydro gel systems
A. Floating systems (gas powered controlled drug delivery systems)
These systems are also known as hydro dynamically balanced systems (HBS) or floating
drug delivery systems (FDDDS).  They have a bulk density lower than density of gastric
fluid,  i.e.  their  bulk  density  is  less  than  1.  The  specific  gravity  of  gastric  fluid  is
approximately 1.004-1.01g/cm, thus FDDS remains buoyant in stomach without affecting
gastric emptying rate for prolonged period of time, releasing the drug slowly at desired
rate.  The improved controlled drug delivery system of the present invention is designed
to deliver effectively a drug to a patient over a specific time period (temporal control) and
from  particular  portion  of  the  patients  gastrointestinal  tract  (spatial  control).   The
improved controlled drug delivery system avoids dose dumping and results in the most
9
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therapeutic  administration of  a particular  drug to a particular  person with a particular
ailment.
Effect of sodium bicarbonate on drug release
      The use of gas generating agents in floating formulations has been tried.  The gas
generating component interacts with an acid source triggered by contact with water or
simply  with  gastric  fluid  to  generate  carbon  dioxide  that  gets  entrapped  within  the
hydrated get matrix of the swelling composition.  The gas generating component such as
carbonates and bicarbonates may be present in amounts from about 5% to about 50%,
preferably from about 10% to about 30%, by weight of the composition.  These salts may
be used alone or in combination with an acid source as a couple.  The acid source may be
one or more of an edible organic acid, a salt of an edible organic acid or mixture thereof
e.g.,  citric acid or its salt sodium citrate or calcium citrate; maleic acid, fumaric acid.
Increasing  the  concentration  of  sodium  bicarbonate  decreases  the  floating  lag  time
because of the faster and higher CO2 generation.  At higher concentration of effervescent
agents  the  coating  of  the  tablets  becomes  less  stable  due  to  increase  in  the  internal
pressure and thereby rupturing the polymer coating.  This causes the sudden increase in
the drug release.
       For the floating system, the ideal dosage form should be coated.  The ideal coating
material should be highly impermeable for the dissolution medium the order to initiate
CO2  formation and should be highly permeable for  generated CO2  in  the wet state to
promote floating. Ichikawa M et al17 reported that sodium bicarbonate not only increases
the hydration in HPMC matrices, but also deviates drug release kinetics from matrix to
zero order. In present study, in acidic media the sodium bicarbonate reacts to generate
carbon dioxide.  This might have contributed to the faster drug release in acidic media.
B. Swelling and expanding drug delivery system
To achieve gastro retention the most promising approach is that of creating a swelling and
expanding system.  Any system will need to expand to a size large enough to be retained
in the (fasted) stomach, but to do so in a safe and reliable manner.  It must not swell or
expand in the esophagus or in the intestine; if it is emptied prematurely from the stomach
(e.g. Problem could arise from the formation of an insoluble mass known to bezoars).
The gastro retentive system will also need to display controlled release properties so that
the drug is released at an appropriate rate for optimal absorption window.  The systems
10
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should have an ability to remain the stomach and withstand the mechanical force therein.
Last but not least, it will need to decrease in size after it has performed its function and
transit through the intestine in the normal way.
C .Bioadhesive Systems
These systems are used to localize a delivery device within the lumen and cavity of body
to enhance  the drug absorption process  in  site  specific  manner.   Various  bioadhesive
polymers are used for achieving the effective bioadhesion.  These polymers tend to form
hydrogen  and electrostatic  bonds at  the mucus membrane-polymers  boundary.   Rapid
hydration contact with the mucoepithelial surface appears to favour adhesion.
D. Modified shape systems
These are non-disintegrating geometric shapes moulded from silastic elastomer or extruded
from polyethylene blends which extend the GRT depending on the size, shape and flexural
modulus of drug delivery system.
E. Mucoadhesive/bioadhesive drug delivery system
 Bioadhesion is the phenomenon in which two materials, at least of which is biological are
held together by means of interfacial, such as adhesion between a polymer and biological
membrane. In the case of polymer attached to the mucin layer of a mucosal tissue, the term
mucoadhesion is used.
Bioadhesive drug delivery systems (BDDS) are used to localize a delivery device within the
lumen to enhance drug absorption in a site specific manner suitable polymers that can be used
to form mucoadhesive  microsphere  include  soluble  and insoluble,  non-biodegradable  and
biodegradable polymers.
F. Superporous hydro gel systems3
Although these are swellable systems, they differ sufficiently from the conventional; types to
warrant separate classification.  With pore size ranging between 10 nm and 10 µm, absorption
of water by conventional hydro gel is a very slow process and several hours may be needed to
reach an equilibrium state during which premature evacuation of the dosage form may occur.
Super  porous  hydro  gels,  average  pore  size>100  µm, swell  to  equilibrium size  within  a
minute, due to rapid water uptake by capillary wetting through numerous interconnected open
11
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pores.  Moreover, they swell to a large size (swelling ratio – 100 or more) and are intended to
have sufficient mechanical strength to withstand pressure by gastric contraction.
This  is  achieved  by  co-formulation  of  a  hydrophilic  particulate  material,  Ac-Di-Sol
(crosscarmellose sodium).  In vivo studies with dogs showed that under fasting condition, the
super porous hydro gel composite (i.e. containing Ac-Di-Sol) remained in the stomach for 2-
3 hrs.   This time increased  to  >24 hrs  after  feeding,  even though the fed condition was
maintained only for a few hours. After several hours (> 30 hrs), fragmentation occurred and
the composite was rapidly cleared.
G. Delayed gastric emptying system
The use of passage-delaying excipients has been proposed as an attempt to develop a form
that exerts some influence on its own transit.   Preliminary in vivo result  depicts a major
problem related to the highly variable inter-subject reactions.  Another analogue approaches
consist  of  using  passage  delaying  drug,  for  example  propantheline,  which  is  generally
considered undesirable because of potential side effects.
12
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Recent Developments in Floating Drug Delivery Systems (FDDS)3,7
The concept of FDDS was described in the literature as early as in 1968; the method was
described for overcoming the difficulty of swallowing medicinal pills.  The suggested method
was providing the pills having a density less than 1.0g/ml so that pill  will float on water
surface.  Since then several approaches have been used to develop an ideal floating delivery
system.
The various buoyant compositions include hollow microspheres (micro balloons), granules,
powders, capsules, tablets (pills), and laminated films.  Most of the floating systems include
single unit  systems, such as HBS and floating tablets.  These systems are unreliable and
irreproducible in prolonging residence time in stomach when orally administered, due to their
`all or nothing’ emptying process.  On the other hand, multiple unit dosage forms appear to
be effective in reducing inter-subject variability and lower the probability of dose dumping.
Based on mechanism of buoyancy, two distinctly types of systems have been utilized in the
development of FDDS.  They are non-effervescent and effervescent types of systems. The
following figures demonstrate these various approaches.
1. Intragastric floating tablet employing hydrophilic swellable polymers
Fig-4 Pictorial diagram for the floating tablet of hydrophilic swellable polymers
13
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2. Floating bilayer tablet containing hydrocolloids in the core 
A bilayer tablet can also be prepared to contain one immediate release and other sustained
release  layer.   Immediate release layer  delivers  the initial  dose whereas  sustained release
layer absorbs gastric fluid and forms a colloidal get barrier on its surface.  This results in
system with bulk density lesser than that of gastric fluid and allows it to remain buoyant in
the stomach for an extended period of time.
Fig-5 Pictorial diagram for the floating bilayer tablet of hydrocolloids
3.  Intragastric floating drug delivery device containing micro porous membrane and 
floatation chamber
The technology is  comprised  of  encapsulation  of  a  drug reservoir  inside a  micro porous
compartment with pores along its top and bottom surfaces.  The peripheral walls of the drug
reservoir  compartment  are  completely  sealed  to  prevent  any  direct  c  contact  of  gastric
mucosal  surface  with  undissolved  drug.   In  stomach,  the  floatation  chamber  containing
entrapped air caused the delivery system to float over the gastric contents. Gastric fluid enters
through the pores, dissolves the drug and carries the dissolved drug for continuous transport
across the intestine for absorption.
14
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4.  Multiple-Unit oral floating dosage system
These buoyant delivery system uilize effervescent reactions between carbonate/bicarbonate
salts and citric/tartaric acid to liberate CO2 which gets entrapped in the jellified hydrochloride
layer of the system, thus decreasing its specific gravity and making it float over chime. These
tablets may be either single layered wherein the CO2 generating components are intimately
mixed  within  the  tablet  matrix  or  they  may  be  bilayer  in  which  the  gas  generating
components are compressed in one hydrocolloid containing layer, and the drug in outer layer
for sustained release effect.  Multiple unit type of floating pills as show in below picture that
generates CO2, have also been developed.  These kinds of systems float completed within 10
min and remain floating over an extended period of 5-6 hrs.
Fig-6 Pictorial diagram for multiple units of floating drug delivery system using gas
generation technique
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  5.  Intragastric osmosis controlled drug delivery system
Intragastric  floating  tablet  that  were  hydrodynamically  balanced  in  the  stomach  for  an
extended  period  of  time  until  the  entire  drug-loading  dose  was  released.   Tables  were
comprised of an active ingredient, 0-80% by weight of inert material, and 20-75% by weight
of  one  or  more  hydrocollids  such  as  methylcellulose,  hydroxyl  ethyl  cellulose,  hydroxyl
propyl methylcellulose, and sodium carboxy methylcellulose, which open contact with gastric
fluid, provided a water impermeable colloid gel barrier on the surface of tablets.
Fig-7 Pictorial diagram for the osmosis controlled gastric floating device
6.  Gastro-inflatable drug delivery device
      These devices are osmotically controlled floating system containing a hollow deformable
unit that can be converted from a collapsed to an expanded position and returned to collapse
position after an extended period.
     A deformable system consists of two chambers separated by an impermeable, pressure
responsive, movable bladder.  The first chamber contains the drug and the second chamber
contains volatile liquid.  The device inflates and the drug is continuously released from the
reservoir into the gastric fluid.
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Fig-8 Pictorial diagram of gastro-inflatable drug delivery device
Advantages of FDDS6,7
1. Sustained drug delivery
2. Site-specific drug delivery
3. Pharmacokinetic advantages
Floating  drug  delivery  offers  several  applications  for  drugs  having  poor
bioavailability  because  of  the  narrow  absorption  window  in  the  upper  part  of  the
gastrointestinal tract.  It retains the dosage form at the site of absorption and thus enhances
the bioavailability.
          Improvement of bioavailability of drugs having poor bioavailability,  because of
restricted absorption in upper GI tract. Minimization of fluctuations in the plasma levels of
drugs due to variable gastric emptying. Improvement of the bioavailability of the drugs that
show pH dependent solubility, such as Verapamil (solubility decreases with increase in pH). 
Therapeutic applications 
            FDDS is effective in the treatment of Helicobacter pylori, causative organism for
chronic gastritis and peptic ulcers.  The eradication of which requires high concentrations of
drug (antibiotics) maintained with the gastric mucosa for a long duration.
17
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Sustained release drug delivery
HBS systems can remain in the stomach for long periods and hence can release the drug over
a prolonged period of time.  The problem of short gastric residence time encountered with an
oral CR formulation hence can be overcome with these systems.  These systems have a bulk
density <1 as a result of which they can float on the gastric contents.  These systems are
relatively large in size and passing from the pyloric opening is prohibited.
Site-specific drug delivery
Floating drug  delivery system is  particularly  advantageous  for  drugs  that  are  specifically
absorbed  from  stomach  or  the  proximal  part  of  the  small  intestine,  e.g.,  riboflavin  and
furosemide.
Absorption enhancement
Drugs that have poor bioavailability because of sites specific absorption from the upper part
of the gastrointestinal tract are potential candidates to be formulated as floating drug delivery
system, thereby maximizing their absorption.  FDDS also serves as an excellent drug delivery
system for the eradication of Helicobacter pylori, which causes chronic gastritis and peptic
ulcers.   The  treatment  requires  high  drug  concentrations  to  be  maintained  at  the  site  of
infection that is within the gastric mucosa.  By virtue of its floating ability these dosage forms
can be retained in the gastric region for a prolonged period so that the drug can be targeted.
Limitations of FDDS
The residence time in the stomach depends upon the digestive state.  Hence, FDDS should be
administered after the meal.16 
The ability to float relies on the hydration state of the dosage form.  In order to keep these
tablets floating  in vivo,  intermittent administration of water (a tumbler full, every 2 hrs) is
beneficial.  
The ability  of  drug to  remain in the stomach depends upon the subject  being positioned
upright. 
FDDS are not suitable for the drugs that have solubility or stability problems in the gastric
fluid. 
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Drugs like nifedipine,  which is  well  absorbed along the entire GIT and which undergoes
significant first pass metabolism, may not be desirable candidates for FDDS since the slow
gastric emptying may lead to the reduced systemic bio-availability.
Drugs that have multiple absorption sites in the gastrointestinal tract, and those that are not
stable at gastric pH are not suitable candidates to be formulated as floating dosage forms. One
drawback  of  hydro  dynamically  balanced  systems  is  that,  this  system  being  a  matrix
formulation consists of a blend of drug and low-density polymers.  The release kinetics of
drug cannot be changed without changing the floating properties of the dosage form and vice
versa.
Marketed products of FDDS
The last three decades of intensive research work have resulted in the development of five
commercial FDDS.
Table-1 Marketed products of floating drug delivery system
Product Name Use
Madopar Anti parkinsonism
Val release Sedative, hypnotic
Liquid Gaviscon Suppress gastrooeseophageal reflux & heart burn
Topalkan Antacid, Antipeptic
Almagate Flotcoat Antacid
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Need for the study
The improved controlled drug delivery system of the present invention is designed to deliver
effectively a drug  to a patient over a specific time period  (temporal control) and from
particular portion of the patients gastrointestinal tract  (spatial control).The improved
controlled drug delivery system avoids dose dumping and results in the most therapeutic
administration of a particular drug to a particular person with a particular ailment.
It is well known to those skilled in the art that for ailments requiring multiple  doses  of  a
particular  drug,  the  blood  levels  of  a  drug  need  to  be maintained above its minimum
effective level and below its minimum toxic level in order to obtain the desired therapeutic
effects, to avoid undesired toxic effects, and to minimize side effects .When the blood levels
of a drug are in this range, the drug is eliminated from  the body at a particular rate. A
controlled drug delivery is usually designed to deliver the drug at this particular rate: safe
and effective blood levels are maintained for a period as long as the system continues to
deliver the drug at this rate. Controlled drug delivery results in substantially constant blood
levels of the active ingredient as compared to the uncontrolled fluctuations observed when
multiple doses of quick releasing doses forms are administered to a  patient.   Controlled
drug delivery results in optimum therapy and not only   reduces the frequency of dosing,
but may also reduce the severity and frequency of side effects.
The above basic concepts of controlled drug delivery are well known to those
 skilled in the
art. Considerable efforts have been made in the last decades to  develop new
pharmaceutically viable and therapeutically effective controlled drug  delivery systems.
Attention has been focused particularly on orally administered controlled  drug delivery
systems.  Various  pharmacokinetic advantages like,  maintenance of constant
therapeutic level over a prolonged period of time and thus reduction in fluctuation in
therapeutic levels minimizing the risk of resistance especially in case of antibiotics. For the
present study cefixime is selected as drug candidate, it fulfills the following characteristics
which indicate its suitability for fabrication into the floating drug delivery system.  Cefixime
is  a  very  poorly soluble   in   water   after  its   oral   administration,   it   is   slowly   and
incompletely absorbed from  the gastrointestinal tract, which resulting into the poor
bioavailability i.e., 40-50%.2, 3, 4 So, in order to improve the therapeutic effect of  the drug
by increasing its bioavailability, we are planning to formulate Cefixime  gas  powered
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systems for controlled release with increased gastric retention.  The  present   development
study  of   Cefixime  in  the  form  of  tablet   or capsule which provides a combination of
spatial and temporal control of drug delivery to patients for effective therapeutic results.18, 19
1.   Formulation of floating tablet containing Cefixime as a drug candidate which would
remain in stomach or upper part of GIT for prolonged period  of  time,  therefore  the
maximum drug release is maintained at desired site. 
2.   Cefixime having good absorption in GIT. 
3.   Cefixime having low pKa which remain unionized in stomach for better absorption.
4. For beta-lactum antibiotics the pharmacodynamic parameter that best  correlates  with
eradication is more than above the MIC (minimum inhibitory concentration). It  means that
the drug should remain in the body above MIC for longer time. 
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2. OBJECTIVES
In the present research work, we are designing Cefixime gas powered systems for controlled
release. It is an object of the present research topic to provide Pharmaceutical composition
in the form of tablets, which constitute an oral controlled drug delivery system.  
1. Generates  and  entraps  a  gas  in  a  hydrated  matrix  upon  contact  with  an aqueous
medium  or   gastric   fluids,   and   which   retains  a   substantially monolithic  form in the
stomach. 
2. Provides increased gastric residence and hence longer period of the drug delivery system
in GI tract. 
3. Delivers the drug at controlled rate such that the drug is delivered over period of time. 
4. Shows increased absorption of drugs i.e. absorbed largely from the upper parts of
the GI tract as compared to other oral controlled drug delivery system. 
5. Safe and effective blood levels are maintained for a period as long as the system continues
to the deliver the drug at this rate. 
6. It not only reduces the frequency of dosing but may also reduce the severity  and
frequency of side effects
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3. REVIEW OF LITERATURE
Talwar et al15developed a once daily formulation for oral administration of ciprofloxacin.
The formulation was composed of 69.9% ciprofloxacin base, 0.34%sodiumalginate, 1.03%
xanthan gum, 13.7% sodium bicarbonate and 12.1% cross linked polyvinyl pyrrolidone. The
viscolyzing agents initially and the gel    forming polymer later formed a hydrated gel matrix
that entrapped the gas, causing the tablet to float and be retained in the stomach or upper part
of the small intestine (spatial control). The hydrated gel  matrix created a tortuous diffusion
path for the drug, resulting in sustained release of the drug.
Baumgartner et al44 (2001) developed floating tablets of ciprofloxacin Hydrochloride offer
a new possibility of treating the stomach infected with Helicobacter pylori. The objective of
this study was to select suitable materials such as polymers hydroxyl ethyl cellulose (HEC),
hydroxyl-propylcellulose (HPC), HPMCK4M and obtained controlled drug release for  more
than  8hr  from  non  disintegrated  matrices  plays  an  important  role  in  prolonging  gastric
residence time. 
H.Zou,  et  al45 Developed  a  floating-pulsatile  drug  delivery  system  intended  for
chronopharmacotherapy.  Floating  pulsatile  concept  was  applied  to  increase  the  gastric
residence of the dosage form having lag phase followed by burst release.  To  overcome
limitations of various approaches for imparting buoyancy,  they generate the system which
consist of three different parts a core tablet containing the active ingredients, an erodible outer
shell  and  a  top  cover  buoyant  layer.  The  buoyant  layer,  prepared  with  methocel  K4M,
Carbopol, 934P, and sodium bicarbonate, provides buoyancy to increase the tension of the
oral dosage form in the stomach. Developed formulations were evaluated for their buoyancy,
mass  degree  of  swelling,  weight  variation,  hardness,  thickness,  friability,  dissolution,
pharmacokinetic parameters. 
Krogel et al46developed floating-pulsatile drug delivery systems based on a reservoir system
consisting of a drug-containing effervescent core and a polymeric coating. Preliminary studies
identified important core and coating properties for the two systems. For the floating system,
a polymer coating with a high elongation value and high water-and low CO2  permeability’s
was selected (Eudragit® RL: acetyltributyl citrate 20%, w:w), while for the pulsatile DDS, a
weak, semi permeable film, which ruptured after a certain lag time was best (ethyl cellulose :
dibutylsebacate  20%,  w:w).  A  polymer  (cellulose  acetate  or  hydroxyl  propyl  methyl
cellulose) was added to the core to control the drug release. The time to  flotation could be
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controlled  by  the  composition  and  hardness  of  the  tablet  core  and  the  composition  and
thickness of the coating. For the pulsatile system, a quick releasing core was formulated in
order  to  obtain  a  rapid  drug
releaseaftertheruptureofthepolymercoating.Thelagtimepriortotherapid  drug  release  phase
increased with increasing core hardness and coating level.
S.S.Badve  et al 47developed a hollow calcium pectinate bead by simple process of acid-base
reaction during ionotropic cross linking. Invivo studies by gamma scintiography determined
on rabbits showed gastro retention of beads up to5h.The  floating beads provided  expected
two-phase release pattern with initial lag time during floating in acidic medium followed by
rapid pulse release in phosphate buffer. This approach suggested the use of hollow calcium
pectinatemicroparticlesaspromisingfloating-pulsatiledrugdeliverysystem  forsite and  time-
specific release of drugs acting as per chronotherapy of diseases. 
B.S.Dave, et  al48optimized  a  gastroretentive  drug  delivery  system  of  ranitidine
hydrochloride.  Guar gum, xanthan gum and  hydroxyl  propyl  methyl  cellulose  were
evaluated  for  gel-forming  properties.  Sodium  bicarbonate  was  in  corporated  as  a  gas-
generating agent. The effects of citric acid and stearic acid on drug release profile and floating
properties were investigated.   Full factorial design was applied to systemically optimize the
drug release profile. The results of the  full  factorial design indicated that allow amount of
citric  acid  and  a  high  amount  of  stearic  acid  favours  sustained  release  of  ranitidine
hydrochloride  from  a  gastro  retentive  formulation.  A  theoretical  dissolution  profile  was
generated using pharmacokinetic parameters of ranitidine hydrochloride. The similarity factor
was applied  between the  factorial design batches and the theoretical dissolution profile. No
significant  difference  was  observed  between  the  desired  release  profiles.  These  studies
indicate that the proper  balance between a release rate enhancer and a release rate retardant
can produce a drug dissolution profile similar to a theoretical dissolution profile.
X.  Xiaoqiang et  al49studied  three  floating  matrix  formulations  of  phenoporlamine
hydrochloride  based  on  gas  forming  agent.  Hydroxy  propyl  methylcellulose
K4MandCarbopol971P NF was  used  in  formulating the  hydro  gel  drug  delivery system.
Incorporation sodium bicarbonate into  matrix resulted in the tablet floating over  simulated
gastric fluid for  more than 6 hr. The dissolution profiles of all tablets showed non-Fickian
diffusion  in  simulated  gastric  fluid.  Invivo  evaluations  of  these  formulations  of
phenoporlamine  hydrochloride  were  conducted  in  six  healthy male  human volunteers  to
compare the sustained release tablets with immediate release tablets.
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Yang et al50 developed as well able asymmetric triple-layer tablet with Floating ability using
hydroxyl  propyl  methyl  cellulose (HPMC) and poly  (ethylene  oxide) (PEO) as the rate-
controlling  polymeric  membrane  excipients.  Tetracycline  and  metronidazole  were  in
corporated into the core layer of the triple-layer matrix for controlled delivery, while bismuth
salt was included in one of the outer layers for instant release. The flotation was accomplished
by incorporating gas-generating layer  consisting of sodium bicarbonate:  calcium carbonate
(1:2ratios) along with the polymers. 
Nur et  al52  developed  floating tablets of  captoprilusing HPMC (4000and 15000cps)  and
carbopol934P. Invitro studies revealed that buoyancy of the tablet is governed by  both the
swelling of the hydrocolloid particles and tablet porosity.  A prolonged release from these
floating  tablets  was  observed  as  compared  with  the  conventional  tablets  and  a  24hrs
controlled release from the dosage form of captopril was achieved. 
Ozdemir  et  al51developed floating bilayer  tablets with controlled release  for furosemide.
One layer contained the polymers HPMC 4000, HPMC 100 and CMC (for the control of the
drug delivery) and the drug. The second layer contained the effervescent  mixture of sodium
bicarbonate  and  citric  acid.  The  in  vitro  floating  studies  revealed  that  the  lesser  the
compression force  the shorter  is  the time of  onset  of  floating,  Radiographic  studies on 6
healthy male volunteers revealed that floating tablets were retained in stomach for 6 hours.
Nur et al  52  developed floating tablets of captopril using HPMC (4000 and 15000cps) and
carbopol 934P. Invitro studies revealed that buoyancy of the   tablet is governed by both the
swelling of the hydrocolloid particles and tablet porosity.  A prolonged release from these
floating  tablets  was  observed  as  compared  with  the  conventional  tablets  and  a  24hrs
controlled release from the dosage form of captopril was achieved.
 Pentewar  et al 68 developed a floating drug delivery system of cefixime trihydrate matrix
tablet using polymer blends of different viscosity grades of HPMC. Gas producing agent used
was sodium bicarbonate. The effect of citric acid on the drug release was also investigated by
dissolution studies. Citric acid was found to be release rate enhancer
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4. DRUG PROFILE
CEFIXIME TRIHYDRATE18,26
STRUCTURE
CHEMICAL NAME: (6R, 7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2- (carboxymethoxy) imino]
acetyl]  amino]  3-ethenyl-8-oxo-5-yhia-1-azabicyclo  [4.2.0]  oct-2-ene-2-carboxylicacid
trihydrates
CATEGORY: Antibacterial
MOLECULAR FORMULA: C16H15N5O7 S2 .3H2o
MOLECULAR WEIGHT: 507.50
DESCRIPTION:  Cefixime  is  a  semisynthetic,  cephalosporin  antibiotic  for  oral
administration. Cefixime is the first member of third generation orally active cephalosporin.
MELTING POINT: 240°-250° C with decomposition
PKa: PKa1-2.10      -COOH of the cephem group
PKa2-2.69     -NH2 of the amino- thiazol group
PKa3-3.73     -COOH of the 7-side chain
ABSORPTION: Well absorbed in gastrointestinal tract
STORAGE: Store in well closed containers, in cool and dry place.
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SOLUBILITY: soluble in  methanol  and  propylene  glycol,  slightly  soluble  in  alcohol  in
acetone and in glycerin
WATER CONTENT: 9% to 12%
IDENTIFICATION: IR absorption spectrum of test samples must comply with cefixime
standard 
PHARMACOKINETICS: 
ABSORPTION: Well absorbed from the gastrointestinal tract
BIOAVAILABILITY: 40 – 50%
DISTRIBUTION: Protein binding approximately 65% 
HALFLIFE: 3 – 4hrs may range up to 9 hrs
 Moderate renal impairment (creatinine clearance of 20ml/min to 40ml/min):
Prolonged to 6.4 hours
 Severe  renal  impairment  (creatinine  clearance  of  5ml/min  to  20ml/min):
Increases to 11.5 hours
EXCRETION: Excretion no biologically active metabolites of cefixime have been identified
in plasma or urine in 24 hours. More than 10% of an administered dose is excreted via bile.
The serum half life of cefixime in healthy subject is 3 – 4 hours.
MECHANISM OF ACTION: Cefixime is a Beta-lactum antibiotic. Its action is by binding
to specific penicillin- binding protein (PBPS) located inside the bacterial cell wall; It inhibits
the third  and last  stage  of  bacterial  cell  wall  autolytic  enzymes  such  as  autolysins;  It  is
possible  that  cefixime interferes  with an autolysin  inhibitor.  As like other  cephalosporin,
bactericidal action of cefixime results from inhibition of cell-wall synthesis.
Cefixime  is  highly  stable  in  the  presence  of  beta-lactamase  enzymes.  As  a  result  many
organisms  resistant  to  penicillin’s  and  some cephalosporin  due  to  the  presence  of  Beta-
lactamase may be active against most strains.
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INDICATIONS AND USAGE:
To  reduce  the  development  of  drug  resistant  bacteria  and  maintain  the  effectiveness  of
Cefixime and other  antibacterial  drugs.  Cefixime should be used only to treat  or prevent
infections that are proven or strongly suspected to be caused by susceptible bacterial
It is indicated in the treatment of the following infections, when caused by susceptible strains
of the designed microorganisms:
 Un complicated UTI caused by Escherchia coli and Proteus mirubillis
 Otitis media caused by Haemophilus influenza(Beta-lactamase positive and negative
strains),  Moraxella (Branhamella),  Catarrhalis,  (Beta-lactamase  positive)  and
S.Pyrogenes
 It  is  used  to  treat  respiratory  tract  infections  (Including  Sinusitis,  Otitis  media,
Pharyngitites, Tonsitities, Pnemonia ), Skin and Soft tissue infections.
ADVERSE REACTIONS:
Gastrointestinal: Symptoms of pseudo-membranous colitis may appear either during or
after antibiotic treatment. Nausea and vomiting have been reported rarely.
Dyspepsia, Gastritis, and Abdominal pain have also occurred. As with sum Penicillins
and sum other Cephalosporins transient hepatitis and Cholestatic, Jaundice have been
reported rarely.
Hypersensitivity: Anaphylactic/ Anaphylactic reactions (including shock and fatalities),
Skin  rashes,  Utricaria,  Drug  fever  ,  Prurities,  Angioedema,  and  Facial  oedema,
Erythema multiform, Stevens- Johnson syndrome and Serum sickness like reactions. A
very serious allergic reaction to this drug is unlikely to occur.
HAEMIC AND LYMPATIC SYSTEM: Transient Thrombocytopenia, Leucopoenia,
Neutropenia, and Eosinophilia, Prolongation in prothrombin time was seen rarely.
HEPATIC:  Transient  elevations  in  SGPT,  SGOT,  Alkaline  phosphatase,  Hepatitis,
Jaundice.
CNS: Headache, Dizziness, Seizures.
RENAL: Transient elevations in BUN/ Creatinine, actual renal failure.
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OTHERS: Genital prurities, Vaginitis, Candidacies, Toxicepidermalnecrolysis.
DRUG INTERACTIONS: Cefixime interactions with several other types of drugs like
Probenecid, Warafin, Live bacterial  vaccines and Carbamazepine. Its medication may
decrease  the effectiveness  of  combination type  birth  control  pills.  This  can  result  in
pregnancy. You may need to use an additional form of reliable birth control while using
this  medication.  Cefixime  medication  may  cause  false  positive  results  with  certain
diabetic  urine testing products  (cupric  sulphate type).  This drug may also affect  the
results of certain lab tests.
DOSAGE AND INDICATIONS:
Adult Dose:
1. Gonorrhoea: Uncomplicated, 400mg orally as one-time dose.
2. Gonorrhoea: Disseminated (after parenteral therapy), 400mg orally twice a day to
complete at least one week of therapy.
3. Active  infective  exacerbation  of  chronic  obstructive  pulmonary  disease:  400mg
orally  once  a  day  or  divided  twice  a  day,  depending  on  type  and  severity  of
infection.
4. Bronchitis: 400mg orally once a day or divided twice a day; depending on type and
severity of infection.
5. Otitis media: 400mg orally once a day or divided twice a day, depending on type and
severity of infection.
6. Tonsilities: 400mg orally once a day or divided twice a day; depending on type and
severity of infection.
7. URINARY TRACT INFECTIOUS DISEASE:  Uncomplicated: 400mg orally once a
day or divided twice a day; depending on type and severity of infection.
Paediatric dose (over 50kgor over 12 years of age consider as a adult)
8. Gonorrhoea: Uncomplicated,(6 months to 12 years  of age)  8mg/kg/day orally as
one-time dose.
9. Gonorrhoea: Disseminated (after parenteraltherapy), (6 months to 12 years of age)
8mg/kg/day orally twice a day to complete atleast one week of therapy.
10. Active infective exacerbation of chronic obstructive pulmonary disease: (6 months to
12 years of age) 8mg/kg/day orally once a day or divided twice a day, depending on
type and severity of infection.
11. Bronchitis:   (6 months to 12 years of age) 8mg/kg/day orally once aday or divided
twice a day; depending on type and severity of infection.
12. Otitis  media:    (6  months  to  12 years  of  age)  8mg/kg/day orally once  a  day ar
divided twice a day, depending on type and severity of infection.
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13. Tonsilities:   (6 months to 12 years of age) 8mg/kg/day orally once a day or divided
twice a day; depending on type and severity of infection.
14. Urinary tract  infectious disease:  Uncomplicated :(  6  months to 12 years  of age)
8mg/kg/day orally once a day or divided twice a day; depending on type and severity
of infection.
 Haemodialysis: 75% of usual dose once a day
 Peritonealdialysis: 50% of usual dose once a day
ADMINISTRATION:
Oral: May be given with or without food.
Oral: If suspension, shake well before measuring the dose
Overdose:  Several  Cephalosporins,  shake  well  before  measuring  the  dose  in  triggering
seizures, particularly in patients with renal impairment, when the dosage was not reduced. If
seizures associated with drug therapy, the drug should 
CONTRAINDICATIONS:  Cefixime is contraindicated in patients with known allergy to
cephalosporin group of antibiotics.
EXCIPIENTS PROFILE
CHITOSAN31,32
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SYNONYMS:
     Chitosan Ascorbate; Deacetylated Chitosan, Enzymatic Polychitosamine Hydrolisat, HEP-
30; Mono-Carboxymethylated Chitosan, N-Carboxybutyl  Chitosan; N,O-Sulfated Chitosan;
O-Sulfated  N-Acetylchitosan;  Quitosano,  Sulfated  N-Carboxymethylchitosan;  Sulfated  O-
Carboxymethylchitosan, Trimethyl Chitosan Chloride.
STRUCTURE: 
BIOLOGICAL SOURCE:
          Chitosan is a sugar that is obtained from the hard outer skeleton of shellfish, including
crab,  lobster,  and  shrimp.  Chitosan,  the  partially  deacetylated  polymer  of  N-acetyl-D-
glucosamine, is water-soluble Chitin (“chiton”, greek) is the primary structural component of
the exoskeletons of crustaceans, molluscs, insects, some fungi and yeast. However, chitin is
not present in higher plants and higher animals. The role played by chitin is similar to the
roles played by cellulose in plants and collagen in higher animals. The annual biosynthesis of
chitin has been estimated to 109 to 1011 tons. Chitin is widely distributed in nature, this is a
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renewable  bioresource.  The shell  of selected crustacean was reported by Knorr (1984) to
consist of 30-40% protein, 30-50% calcium carbonate and calcium phosphate, and 20-30%
chitin. The main commercial sources of chitin are the shellfish waste such as shrimps, lobster,
crabs, squid pens, prawns and crawfish. Chitosan is found in nature, to a lesser extent than
chitin, in the cell walls of fungi. Chitin is economically feasible and ecologically desirable
because large amounts of shell wastes are available as a by-product of the seafood industry.
Production  of  chitosan  from  these  is  inexpensive  and  easy.  Commercially,  chitosan  is
available in the form of dry flakes, solution and fine powder.
Crab/Shrimp shells
↓
Demineralization (dilute HCl)
↓
Deproteination (dilute NaOH)
↓
Decolourisation (dilute KMnO4)
↓
Chitin
↓
Deacetylation (concentrated NaOH)
↓
Chitosan
     It  is  a  linear polysaccharide composed  of  randomly  distributed  β-(1-4)-linked D-
glucosamine   (deacetylated unit) and N-acetyl-D-glucosamine 
CHEMISTRY
       Chitin consists mainly of unbranched chains of beta-(1 → 4)-2-acetamido-2-deoxy-D-
glucose  (=N-acetyl-d-glucosamine).  It  is  similar  to  cellulose,  in  which  the  C-2  hydroxyl
groups  are  replaced  by acetamido residue.  Chitin  is  practically  insoluble  in  water,  dilute
acids, and alcohol, with variation depending on product origin.
PHYSICO-CHEMICAL PROPERTIES
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Chitosan is actually a denomination describing a series of polymers with different degree of
deacetylation and molecular weight. These two factors are very important for the Physico-
chemical properties of chitosan.
1. Description
Chitosan occurs as odourless. The pigment in the crustacean shells forms complexes with
chitin. Then, chitosan is a quite flabby powder or flake and its color varies from yellow to
white whereas spray-dried chitosan salts have smooth texture, fine powder and pale color.
2. Degree of Deacetylation:
The process of deacetylation involves the removal of acetyl groups from the molecular chain
of chitin, leaving behind a compound (chitosan) with a high degree chemical reactive amino
group (-NH2). This makes the degree of deacetylation (DD) an important property in chitosan
production  as  it  affects  the  physicochemical  properties,  hence  determines  its  appropriate
applications. Deacetylation also affects the biodegradability and immunological activity.
3. Molecular Weight
Molecular  weight  of  native  chitin  is  usually  larger  than  one  million  Daltons  while
commercial  chitosan  products  have  the  molecular  weight  range  of  100,000  –  1,200,000
Daltons, depending on the process and grades of the product
4. SOLUBILITY: 
 Chitosan is a weak base with is also hydrophilic. The D-glucosamine
unit has a pKa value of 7.5 (Säkkinen 2003: 1-56). The basic nature of Chitosan depends on
its degree of deacetylation an apparent pKa value for the polymer is 6.5. It is estimated that
deacetylation must be at least 85% complete in order to achieve the desired solubility. Low-
molecular weight Chitosan (MW <10 KDa) and chitosan salts may be more readily soluble,
but  high  MW  Chitosan  were  occured  gel  formation.  Chitosan  is  soluble  in  dilute  and
concentrated solutions of most organic acids and to some extent in mineral inorganic acids
(including hydrochloric,  lactic,  glutamic and aspartic  acids)  that  form water-soluble salts.
Chitosan salts are soluble in water; the solubility depends on the degree of deacetylation and
the pH of the solution
USES 
There is some evidence of the effect of chitosan on lowering cholesterol and body weight, but
the effect is unlikely to be of clinical importance. To some extent, chitosan is used in the
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emergency  setting  to  control  bleeding.  Chitosan  has  been  used  in  various  drug  delivery
systems. Antimicrobial and other effects are being evaluated for use in dentistry.
Pharmaceutical applications of Chitosan 
 Chitosan  in  the  pharmaceutical  industry  is  used  to  mask  bitter  tastes  in  oral
pharmaceuticals. Chitosan being employed in various types of drug delivery systems,
including intranasal, transdermal, and site-specific delivery mechanisms, as well as in
hydrogels, microspheres, liposomes, matrix forms, and conjugate forms. 
 Diluent in direct compression of tablets 
 Binder in wet granulation 
 Slow-release of drugs from tablets and granules
 Drug carrier in micro particle systems 
 Films controlling drug release 
 Preparation of hydro gels, agent for increasing viscosity in              solutions
 Wetting agent, and improvement of dissolution of poorly  soluble drug substances
 Disintegrants
 Bioadhesive polymer 
 Site-specific drug delivery(e.g. to the stomach or colon)
 Absorption enhancer(e.g. for nasal or oral drug delivery)
 Biodegradable polymer(implants, micro particles)
 Carrier in relation to vaccine delivery or gene therapy
 Being a bioadhesive  polymer  and having antibacterial  activity,  chitosan  is  a  good
candidate for  oral  cavity drug delivery.  Also,  because  of  its  favourable  biological
properties,  chitosan is  using for  the enhancement  of  drug absorption  in buccal  or
sublingual delivery systems.
  Chitosan microspheres can remain longer in stomach and allow for stomach-specific
drug delivery. This polymer could have promising application in colon-specific drug
delivery. As a result of the physical, chemical and biological properties, chitosan has
been using many different formulations for drug and gene delivery in the GI tract.
TOXICOLOGY
Chitosan's toxicity profile is relatively low. 
Dietary chitosan reportedly affects calcium metabolism in animals
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SIDE EFFECTS
Side  effects  of  chitosan  following  oral  administration  relate  to  its  effects  within  the
gastrointestinal tract. Consumption of several grams of chitosan daily by humans can result in
constipation or  diarrhoea,  because  chitosan entraps  water  and  lipids  in  the  intestine.  The
amounts of chitosan needed in pharmaceutical formulations are fairly low (less than 1000
mg/dose), and risks of side effects in the gastrointestinal tract are therefore also low.
INCOMPATIBILITIES:
Chitosan is clinically well tolerated, it has been suggested that it might not be desirable for
administration to individuals allergic to crustaceans,  in which consumption of crustaceans
frequently results in allergic reactions, and serious adverse reactions are possible.
Sodium bicarbonate31,32
Structure:
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            Sodium bicarbonate natural mineral  form is nahcolite. It  is a component of the
mineral natron and is found dissolved in many mineral springs. It is found in dissolved form
in bile,  where  it  serves  to  neutralize  the  acidity of  the hydrochloric  acid produced  by the
pancreas, and is excreted into the duodenum of the small intestine via the bile duct. It is also
produced artificially..
IUPAC name: Sodium hydrogen carbonate
Other names Baking soda, bicarbonate of soda, nahcolite, sodium bicarbonate, E500,
Functional category: alkalizing agent, Therapeutic agent
Molecular formula: NaHCO3
Molar mass - 84.01 g mol−1
Bulk density               -  0.869 g/ cm
Tapped density   - 1.369 1.369g/ cm
True Density              - 2.173 g/ cm
Melting point              - 50 °C, 323 K, 122 °F (decomposes)
Boiling point  - 851 °C, 1124 K, 1564 °F
Solubility                    - Insoluble in ethanol and ether, soluble in water - 9 g/100 mL, 
69 g/L (0 °C), 96 g/l (20 °C), 165 g/l (60 °C), 236 g/L (100 °C)
Acidity (pKa): 10.329- 6.351 (carbonic acid) 
Refractive index : 1.3344
Routes of administration: Intravenous, oral
Description: Sodium bicarbonate  is  a  white  solid  that  is crystalline,  odourless,  but  often
appears as a fine powder. It has a slightly salty, alkaline taste resembling that of washing soda
(sodium carbonate). 
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Chemistry: Sodium  bicarbonate  is  an amphoteric compound.  Aqueous  solutions  are
mildly alkaline due to the formation of carbonic acid and hydroxide ion:
HCO3 + H2O → H2CO3 + OH−
Sodium bicarbonate can be used as a wash to remove any acidic impurities from a "crude"
liquid, producing a purer sample. Reaction of sodium bicarbonate and an acid produce a salt
and carbonic acid, which readily decomposes to carbon dioxide and water:
NaHCO3 + HCl → NaCl + H2CO3
H2CO3 → H2O + CO2 (g)
Sodium  bicarbonate  reacts  with acetic  acid (found  in vinegar),  producing sodium  acetate,
water, and carbon dioxide:
NaHCO3 + CH3COOH → CH3COONa + H2O + CO2(g)
Sodium bicarbonate reacts with bases such as sodium hydroxide to form carbonates:
NaHCO3 + NaOH → Na2CO3 + H2O
Sodium bicarbonate  reacts  with carboxyl  groups in  proteins  to  give  a brisk effervescence
from the formation of CO2. This reaction is used to test for the presence of carboxylic groups
in protein
Pharmaceutical applications:
        It is generally used in pharmaceutical formulations as a source of carbon dioxide in
effervescent  tablets  and  granules  it  is  also  used  in  tablet  formulations  to  buffer  drug
molecules that are weak acids, thereby increasing the rate of tablet dissolution and reducing
gastric irritation. Recently, sodium bicarbonate has been used as a gas forming systems and in
floating oral controlled release oral dosage forms of furosemide and cisapride.
Stability and storage conditions:
     Sodium bicarbonate powder is stable below 76% relative humidity at 25 and below 48%
relative  humidity  at  4°C.  Aqueous  solutions  of  Sodium bicarbonate  may be  sterilized  by
filtration  or  autoclaving.  To  minimize  decomposition  of  Sodium  bicarbonate  by
decarboxyation  autoclaving,  carbon  dioxide  is  passed  through  the  solution  in  its  final
container,  which  is  than  hermetically  sealed  and  autoclaved  aqueous  solutions  of  sodium
bicarbonate stored in glass containers may develop deposits of small glass particles. Sodium
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bicarbonate is stable in dry air but slowly decomposes in moist air and should therefore be
stored in a well closed container in a cool, dry place.
Incompatibilities:
      Sodium bicarbonate reacts with acids, acidic salts, and many salts, with the evolution of
carbon dioxide.  
Adipic acid31
IUPAC name: hexanedioic acid 
Structure  
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Molecular formula       C6H10O4
Molar mass                 146.14 g mol−1
Density                       1.36 g/cm3
Melting point: 152.1 °C, 425 K, 306 °F
Boiling point: 337.5 °C, 611 K, 640 °F
Acidity (pKa):     4.43, 5.41
LD50 :                          3600 mg/kg (rat)
Pharmaceutical Applications of adipic acid:  
       By far the majority of the 2.5 billion kg of adipic acid produced annually is used as
monomer for  the production of nylon by a polycondensation reaction with hexa methylene
diamine forming 6, 6-nylon. Other major applications also involve polymers: it is a monomer
for production of Polyurethane and its esters are plasticizers, especially in PVC.
In medicine
Adipic acid has been incorporated into controlled-release formulation matrix tablets to obtain
pH-independent  release  for  both weakly basic and weakly acidic  drugs.  It  has  also been
incorporated into the polymeric coating of hydrophilic monolithic systems to modulate the
intra  gel  pH,  resulting  in  zero-order  release  of  a  hydrophilic  drug.  The  disintegration  at
intestinal pH of the enteric polymer shellac has been reported to improve when adipic acid
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was  used  as  a  pore-forming  agent  without  affecting  release  in  the  acidic  media.  Other
controlled-release formulations have included adipic acid with the intention of obtaining a
late-burst release profile
In foods
Small but significant amounts of adipic acid are used as a food ingredient as a flavorant and
gelling aid. It is used in some calcium carbonate antacids to make them tart.
Safety: Adipic acid, like most carboxylic acids, is a mild skin irritant. It is mildly toxic, with
an LD50 of 3600 mg/kg for oral ingestion by rats.
METHYLCRYSTALLINE CELLULOSE31
 Non-proprietary names 
BP: Microcrystalline cellulose
Ph. Eur.  Cellulosum microcrystallinum
USPNF: Microcrystalline cellulose
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Synonyms:  Avicel;  Cellulose  gel;  crystalline  cellulose;  E460;  Emcocel,  Fibrocel;  Tables;
Vivacel
Empirical formula: C6H10O5
Structure of microcrystalline cellulose
Category: Tablet disintegrant (5 -15%), adsorbent, tablet and capsule diluents.
Description: The colour of the lactose is white to off-white crystalline particles or powder.
MCC is odourless.
Properties:
Density: 1.540 to 1.589 g/cm3
Solubility: Practically insoluble in chloroform, Ethanol and 1 in 4.63 g of Water
Stability and Storage: Under humid conditions (80% and above) mould growth may occur.
MCC may develop a brown coloration on storage, there action is accelerated by Warm and
damp conditions. It should be sorted in a well closed container in a cool, dry place.
Safety: It is regarded as a non-toxic and non-irritant material. Adverse reactions may be seen
in persons with deficiency of intestinal enzyme lactase.
LACTOSE34
Synonyms: Aero flow, fast flow, flow lac, milk sugar
Empirical formula     : C11 H22 O11 .H2 O
Functional category   : Tablet and capsule diluents and channeling agent
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Applications in pharmaceutical technology:
     Lactose is widely used as filter diluents in tablets, capsules and to a more limited in
lyophilized products and infant-feed formulas.
      Direct compression grades are generally composed of spray-dried lactose, which contains
specially  prepared  pure  lactose  monohydrate  along  with  a  small  amount  of  amorphous
lactose.
Description: white  to  off-white crystalline  particles  or  powder.  Lactose  is  odourless  and
slightly sweet taste.
Physical properties:
Bulk Density     :                  0.62 g/cm3
Tapped density:                 0.94   g/cm3
True density: 1.522 g/cm3
Specific rotation: + 52° to +52.6°
Solubility : highly soluble in water, practically insoluble in chloroform, ethanol, and ether.    
Stability and storage conditions:
     Lactose may develop a brown coloration on storage, the reaction being accelerated by
warm dap conditions. Lactose should be stored in a well-closed container in a cool, dry place.
XANTHAN GUM29,32
Non-proprietary: USPNF: xanthan gum 
Synonyms: Corn  sugar  gum;  E415;  Keltrol;  Merezan;  polysaccharide  B-1459;  Rhodigel;
xanthan gum
Emperical formula: The USPNF XVII describes xanthan gum as a high molecular weight
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polysaccharide gum. It  contains D- glucose and D-mannose as the dominant hexose units,
along with D-glucuronic acid, and is prepared as the sodium, potassium, or calcium salt.
Molecular weight: 2 × 106
Functional category: stabilizing agent, suspending agent, viscosity-increasing agent.
Description: xanthan gum occurs as a cream or white-coloured, odorless, free flowing, and
fine powder.
Typical properties: 
Solubility: practically insoluble in ethanol and ether; soluble in cold or warm water.
Viscosity: 1200 -1600 mPa s (1200 – 1600) for a 1% w/v aqueous solution at 25°C.
Stability and storage condition:  Xanthan gum is a stable material. Aqueous solutions are
Stable over a wide pH range (pH 3 – 12) 
Safety: xanthan  gum  is  widely  used  in  oral  and  topical  pharmaceutical  formulations,
cosmetics and food products  and is  generally  regarded  as  non-irritant  at  the employed  as
pharmaceutical excipients.
SODIUM ALGINATE32,33
Structure:
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          It is a linear copolymer with homopolymeric blocks of (1-4)-linked β-D-mannuronate
(M) and its C-5 epimer α-L-guluronate (G) residues, respectively, covalently linked together
in different sequences or blocks
Molecular formula:   C6H8O6)n
Molar mass:      10,000 - 600,000
Density :           1.601 g/cm3
‘Acidity (pKa):   1.5-3.5
Description: Alginic  acid,  also  called algin or alginate,  is
an anionic polysaccharide. The chemical  compound sodium  alginate is  the sodium salt of
alginic  acid,  Its  colour  ranges  from white  to  yellowish-brown.  It  is  sold  in filamentous,
granular or powdered forms.
Viscosity:  It  distributed widely in the cell walls of brown algae, where it,  through binding
water,  forms  a  viscous gum. In  extracted  form it  absorbs  water  quickly;  it  is  capable  of
absorbing 200-300 times its own weight in water.
Application in pharmaceutical formulation or technology: 
Sodium alginate is used in a variety of oral and topical pharmaceutical formulations. In tablet
formulation sodium alginate may be used as both binder and disintegrates it has been used as a
diluents in capsule formulation. 
Sodium alginate has also been used in preparations of sustained release oral formulations since
it can delay the dissolutions of a drug from tablets capsules and aqueous suspensions. 
In topical formulations sodium alginate is widely used as a thickening and suspending agent in
a variety of pastes, creams, and gels, and as a stabilizing agent for oil-in-water emulsions.
TALC33
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         Talc is a mineral composed of hydrated magnesium silicate with the chemical formula
H2Mg3  (SiO3)4 orMg3Si4O10(OH)2.Soapstone is a metamorphic rock composed predominantly
of talc.
Synonym: Magsil Osmanthus, powder talc, purified French chalk, purtalc, oapstone; Steatite
Empirical formula: Mg (Si2O5)4(OH)4
Category Silicate mineral, anticaking agent, glidant, tablet and capsule diluents, tablet and
capsule lubricant.
Description: talc  is  very  fine,  white  to  grayish-  white  coloured,  odourless,  crystalline
powder. It adheres to the skin, is soft to the unch and free from grittiness.
Chemical formulaMg3 Si4 O10 (OH)2
Crystal symmetry   Either monoclinic 2mr triclinic
Identification: 
Colour: Light to dark green, brown, white
Crystal habit: Foliated to fibrous masses, rare as platey to pyramidal crystals
PROPERITIES:
Density: 0.536 – 0.862 gm/cm3
pH: 6.5 – 10  for a 20% w/w aqueous dispersion
Solubility: practically insoluble in dilute acids, alkalies, organic solvents and water.
Storage and Stability: Talc is stable material and may be sterilized by heating at 1600°C for
not  less  than  1  hrs.  It  may  also  be  sterilized  by  exposure  to  ethylene  oxide  or  gamma
irritation. Talc should be stored in a well-closed container in a cool, dry place.
Applications of talc:
• Talc  is  also  used  as food  additive or  in  pharmaceutical  products  as  a glidant.  In
medicine  talc  is  used  as  a pleurodesis agent  to  prevent  recurrent pleural
effusion or pneumothorax.
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• Talc is used in many industries such as paper  making, plastic,  paint and coatings,
rubber,  food,  electric  cable,  pharmaceuticals,  cosmetics,  ceramics,  etc.  A  coarse
grayish-green  high-talc  rock  is soapstone or  steatite  and has  been  used  for  stoves,
sinks, electrical switchboards, crayons, soap, etc.
•  It is often used for surfaces of lab counter tops and electrical switchboards because of
its resistance to heat, electricity and acids. 
• Talc  finds  use  as  a cosmetic (talcum  powder),  as  a  lubricant,  and  as  filler
in paper manufacture.  Talc  is  used  in baby  powder,  an astringent powder  used  for
preventing rashes on the area covered by a diaper (see diaper rash). It  is also often
used in basketball to keep a player's  hands dry.  Most tailor's chalk is talc, as is the
chalk often used for welding or metalworking.
• Talc is widely used in the ceramics industry in both bodies and glazes. In low-fire art
ware bodies it imparts whiteness and increases thermal expansion to resist crazing.
Safety 
• Talc  powder  is  a  household  item,  sold  globally  for  use  in  personal  hygiene  and
cosmetics and used by many millions every year. Some suspicions have been raised
about the possibility its use promotes certain types of diseases, mainly cancers of the
ovaries and lungs. 
•  The  studies  reference,  by  subject: pulmonary issues, lung  cancer, skin
cancer and ovarian  cancer. One  of  these,  published  in  1993,  was  a  US  National
Toxicology  Program  report,  which  found  that  cosmetic  grade  talc  containing  no
asbestos-like  fibres  was  correlated  with  tumour  formation  in rats (animal  testing)
forced to inhale talc for 6 hours a day, five days a week over at least 113 weeks. A
1971 paper found particles of talc embedded in 75% of the ovarian tumors studied 
• The US Food and Drug Administration (FDA) considers talc (magnesium silicate) to
be generally recognized as safe (GRAS) for use as an anti-caking agent in table salt in
concentrations smaller than 2%.
CARBOPOL29,33
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  Structure:                  
     Carbopol-934, a synthetic high molecular weight, non-linear polymer of acrylic acid
cross-linked with polyalkenyl polyether with average molecular weight 3×106 Daltons. It
contains not less than 56% and not more than 68% of carboxylic acid (-COOH) groups.
Synonym: Acritamer, Acrylic acid polymer carboxyl vinyl polymer
Non proprietary names:
BP    : carbomer, 
USP: carbomer
Chemical name: carboxyl polymethylene
Empirical formula: (C3HO) (-C H -Sucrose)
Category: Bioadhesive,  Emulsifying,  suspending  & viscosity  enhancing  agent,  tablet
binder and release-modyfing agent
Description: white, fluffy, acidic, hygroscopic powder with a slight characteristic odour
Solubility: After  neutralization with alkali  hydroxides or amines,  soluble in water,  in
ethanol (96%) and in glycerol.
PH:     2.5-3.0 (1% aqueous solution)
Glass transition temperature: 100-105°C
Melting point: Decomposition occurs within 30 min at 260°C
Specific gravity: 1.41
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Viscosity: Carbomers  disappears  in  water  to  form  acidic  colloidal  solutions  of  low
viscosity which when neutralized produce highly viscous gels. 29, 400 to 39,400 cps at
25°C (0.5% neutralized aqueous solution)
Stability and storage: Carbomers are stable, though hygroscopic materials and can be
heated at temperatures below 104°C for up to 2 hours without affecting their thickening
efficiency.
Applications: It is used as thickening, emulsifying and gelling agent. It is used as a tablet
binder and matrix forming agent in sustained – release formulations affording zero- to
near – zero – order release. It  is used as the bioadhesive component in muco adhesive
ointments, gels and tablets.
Safety: Carbomers are regarded as nontoxic and non irritant.
MAGNESIUM STERATE33
Synonyms: magnesium octadecanoate, stearic acid magnesium salt
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Empirical formula: C36 H70 MgO4
Structure: 
Molar mass      591.34
‘Functional category: Tablet and capsule lubricant  
Description: Magnesium stearate is a fine; white precipitated or milled impalpable powder
with   low bulk density. The powder is greasy to touch and readily adhere to skin.
Bulk density: 0.159 gm/cm
Tapped density: 0.286 gm/ cm
True density: 1.092 gm/cm
Solubility: Slightly soluble in warm ethanol (95%); practically insoluble in ether, and water.
Melting range   : 117-150
Applications in pharmaceutical formulation
It is widely used in cosmetics, foods and pharmaceutical formulations. Primary use is as a
lubricant in capsule and tablet manufacturing at concentration between 0.25 – 5.0%
Storage conditions: Store in a well closed container in a cool & dry place
Incompatibility: Magnesium stearate is incompatible with strong acids, alkalis and iron salts.
It cannot be used in products containing most alkaloidal salts. Aspirin, certain vitamins and
most alkaloidal salts.
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Safety: It is widely used as a pharmaceutical excipient and is regarded as non-toxic for oral
administration. Oral consumption in large amount may result in laxative effect  or mucosal
irritation.
Handling  precautions: Eye  protection  and  hand  gloves  are  recommended.  Magnesium
stearate  should  be  handled  in  a  well-  ventilated  environment,  a  respirator  mask  is
recommended.
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5. METHODOLOGY
All the material used was of pharmaceutical or analytical grade (PR/AR)
Table – 2 Chemical and Excipients used
Name of chemicals Received from
Cefiximetrihydrate  Hyderabad
Chitosan Hyderabad
Sodium alginate  S.D. Fine chemicals, Mumbai
Adipic acid  S.D. Fine chemicals, Mumbai
Crosscarmellose sodium  Rajesh chemicals Mumbai
Sodium bicarbonate  S.D. Fine chemicals, Mumbai
Talc  S.D. Fine chemicals Mumbai
Magnesium stearate  S.D. Fine chemicals Mumbai
Xantham gum Mumbai
Carbopol934  Hi Media Chem. Pvt. Ltd Mumbai
Table-3 List of instruments/equipments used
Name of instruments/ equipments Source
Electronic Balance BT 220H Shimadzu, Japan
UV visible spectrophotometer Shimadzu1800
Compression machine RimekMinipress II MT
FTIR Perkin Elmer 1600 series
Dissolution test apparatus EletrolabTDT-06
Friability Test Apparatus 020334 -Veego Digital
Hardness tester Pfizer
Verniercaliper Aerospace
Stability Chamber Thermal Lab, Mumbai
Thickness tester Screw Gauze
Analytical methods for the estimation of Cefixime:
Detection of Absorption Maxima (max): The samples of the standard solution were scanned
between 200-400 nm regions on Schimadzu 1800 UV spectrophotometer.  The absorption
maximum for 0.1N HCL was found to be 288nm
Preparation of standard calibration curves:
The standard calibration curve for Cefixime was prepared by using Methanol and 0.1N HCL
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Calibration curve for the estimation of Cefixime in methanol
In this method, the drug Cefixime was dissolved in little amount of methanol to get the clear
solution, volume was adjusted with methanol. Then the maximum absorbance was measured
at 288nm. Bear’s law obeyed in the concentration range 3 to 15 mcg/ml
Standard solution:
Dissolve 50 mg of Cefixime in few ml of methanol in 50 ml volumetric flask. The volume
was adjusted to 50 ml methanol
Stock solution
The resultant solution subsequently diluted with methanol to get concentration of 3, 6, 9, 12
and 15 mcg/ml. the absorbance of above said concentration solution was measured at 290 nm
using  methanol  as  blank.  The  concentration  of  Cefixime  solution  and  corresponding
absorbance 
Calibration curve for the estimation of Cefixime in 0.1N HCl:
In this method the drug Cefixime was dissolved in little amount of 0.1N HCl to get a clear
solution. Volume was adjusted with 0.1N HCl. Then maximum absorbance was measured at
288nm, bear’s law obeyed in the concentration range3 to 15 mcg/ml.
Reagents: Cefixime, 0.1N HCl
Standard solution
Dissolve 50 mg of Cefixime in few ml of 0.1N HCL in 50 ml volumetric flask. The volume
was adjusted to 50 ml with 0.1N HCL
Stock solution:
The resultant solution is filtered with Whatman filter paper subsequently diluted with 0.1N
HCl  get  concentration  of  3,  6,  9,  12  and  15  mcg/ml  the  absorbance  of  above  said
concentration solution was measured at 288nm using0.1N HCl as blank. The concentration of
Cefixime solution and corresponding absorbance
Table-4 Standard calibration data of cefixime in methanol
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              Concentration   (mcg/ml)                   Absorbance
0 0
3 0.127
6 0.265
9 0.368
12 0.512
15 0.628
18 0.756
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Fig-9 Standard calibration data of cefixime in 0.1 N HCL
Table-5 Absorbance values for standard Cefixime in Hcl
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              Concentration              
                   (mcg/ml)     
Absorbance
0 0
3 0.138
6 0.265
9 0.378
12 0.512
15 0.656
18 0.834
Methodology
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Standard calibration data of cefixime in 0.1 N HCL
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Fig-10 Standard calibration data of cefixime in 0.1 N HCL
Preformulation study:
Almost  all  the  drugs  which  are  active  orally  are  marketed as tablets capsules or both.
Prior to development of dosage forms with a new drug candidate, it is essential that certain
fundamental  physical  and  chemical  properties  of  the  drug  molecule  and  other  derived
properties  of  the drug powder are determined.  This information will  dictate  many of  the
subsequent events and possible approaches in formulation development.
Preformulation study of Cefiximetrihydrate
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Physiochemical properties of Cefiximetrihydrate
Official status official in USP and BP
Description: Cefixime is off-white to pale yellow powder
pH: pH measured by calibrated pH meter of a solution containing the drug equivalent of 0.7
mg per ml in water.
Identification tests
UV Spectrum:  Cefixime in methanol shows maximum absorbance at 289.2 nm similar to
reference spectrum
IR spectrum: The IR spectra is concordant with the reference spectrum of Cefixime
Melting point: The melting point of Cefixime was determined by capillary method
Preparation of 0.1N HCl: 0.1N HCl was prepared according to IP 1996. A quantity of 8.5
ml of HCl was diluted with fresh distilled water to produce 1000 ml.
Evaluation of dry mixed powder for precompressional parameters
Pure  Cefixime  and  its  physical  mixture  with  different  excipients  as  mixed  in  different
formulas from F1 to F10 were evaluated for angle of repose, bulk density, tapped density,
Hausner ratio, Carr’s index, degree of homogeneity of blend.
Angle of repose
Angle of repose is the angle of inclination, formed to the flat surface by the bulk powder
when it is allowed to flow under gravitational force from a fixed height. It is a characteristic
of dry mixed powder flow properties.
The angle of repose of pure Cefixime and prepared mixture was determined by fixed funnel
method
Ɵ= Tan¯ 1 h/r
Ɵ                                        = Angle of repose
h = Height of granules above the flat surface
r = Radius of the circle formed by the granule
Bulk density:
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Bulk density is the ratio of mass to volume of material. Bulk density of pure Cefixime and
prepared mixture was determined by pouring pre-weighed powder in to a graduated cylinder.
Bulk density was determined by measuring poured volume of powder and mass of powder
used.
Ρ b = M /Vb
Where,
Ρ b  =Bulk density
Vb = Volume of bulk
M = Mass of powder.
Tapped density: Tapped density was determined by placing a known mass of mixed powder
into the graduated cylinder and which is operated for fixed number of taps (100) until the
powder bed volume has reached a minimum. Then by measuring the volume, tapped density
was determined by using the formula.
Pt = M / Vt
Where,
Pt = Tapped density
Vt- Tapped volume
Hausner ratio
It is a simple index that can be determined on small quantity of powder and flow properties of
powder may be interpreted. It was calculated by using
Hausner ratio = TBD/ LBD ×100
Carr’s index:
It  is  a  simple  index  that  can  be  determined  on  small  quantity  of  powder and flow
properties of powder may be interpreted.
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Carr’s index = TBD- LBD/ LBD×100
Excipients Compatibility study
FTIR studies: The  successful  formulation  of  a  suitable  and  effective  solid  dosage  form
depends  upon  the  careful  selection  of  the  excipients.  Excipients  are  added  to  facilitate
administration, promote the consistent release and bioavailability of drug. It’s necessary to
study the compatibility of excipients with drug. Here IR spectroscopy was used to investigate
and predict any physicochemical interaction between components in a formulation and to the
selection of suitable compatible Excipients selection of suitable compatible Excipients
FTIR  studies  were  conducted  and  the  spectrum  was  recorded  in  the wavelength region
of  4000 to  400 cm-1  .  The  procedure  consisted  of,  dispersing a  sample  (drug alone,  and
mixture of drug and polymers in KBr and compressing into discs by applying a pressure of 7
tons for 5 min in a KBr press. The pellet was placed in the light path and the spectrum was
obtained.
Differential Scanning Colorimetry:
DSC scan of about 5mg, accurately weighed Cefixime and formulation F10 were performed
by  using  an  automatic  thermal  analyzer  system.  (DSC60  Shimadzu  Corporation,  Japan)
Sealed and perforated aluminium pans were used in the experiments for  all  the samples.
Temperature calibrations were performed using indium as standard. An empty pan sealed in
the same way as for the sample was used as a reference. The entire samples were run at a
scanning rate of 10°C/min from 50-300°C
METHOD OF PREPARATION
Preparation of Floating tablets of Cefixime15, 18
According to the present invention, the controlled gas powered system (CGPS) includes a
swelling agent carbopol and a gel forming polymer. Together these agents form a hydrated
gel  matrix.  The  CGPS  further  contain  sagas  generating  component  such  that  a  gas  is
57
Methodology
generated in a controlled manner and is entrapped in hydrate gel matrix.. The gas generated
by sodium bicarbonate also causes  matrix  expansion. However,  in the  present invention,
swelling of matrix is controlled by the  viscolyzing agent (xanthangum), which acts both as
swellability  and  release  controlling  agent.  The  gas  generating  component  sodium
bicarbonate interacts with an acid source citric acid by contact with gastric fluid to generate
carbondioxide  that  gets  entrapped  within  the  hydrated  gel  matrix  of  the  swelling
composition. In the present invention, it has found that a xanthan gum helps in maintaining
tablet integrity, when stirred in aqueous medium. The sodium alginate gel forming polymer
cross-links with time to form a stable structure which entraps the generated gas. Thus, with
the passage of time, the gel forming polymer results in hydrodynamically balanced system
whereby  the  matrix  system  is  retained  in  the  stomach  for  extended  period  of  time.
Simultaneously, the viscolyzing agent and gel forming polymer provide a tortuous diffusion
pathway for the drug there by resulting in controlled drug release. The hydrophilic polymers
are useful in the present invention in modifying the rate of release of the drug from tablet.
Various concentrations of Chitosan were reported to have duration of buoyancy of more than
8 hours in the simulated meal medium, as well as in distilled water.
In order to retain the dosage form in the stomach for a long period of time and to avoid
erosion  and  dissolution,  xanthan  gum  and  Carbopol  were  used  as  a  gelling  agent  in
combination with Chitosan to retard the drug release.  The hydrophilic polymers such as
carbopol, chitosan are used in the present invention in modifying the rate of release of the
drug from the tablets. Sodium bicarbonate (NaHCO3) was incorporated in the formulation in
such a way that when in contact with the acidic gastric contents, CO2 is liberated and gets
entrapped in swollen hydrocolloids, which provides buoyancy to the dosage form. Lactose
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was   included   in   formulation   as   hydrophilic   agent,   with assumption that capillary
action of lactose  may facilitate higher drug release without affecting the  matrix (floating
ability), the incorporation of lactose showed appropriate release and floating time. In all the
formulations designed weight of a single tablet was kept constant. The weight of a single
tablet was 600 mg.
Table-6 METHOD OF PREPARATION-FORMULA
Preparation of Floating tablet of Cefiximetrihydrate
INGREDIENTS F1
mg
F2
mg
F3
Mg
F4
mg
F5
Mg
F6
mg
F7
mg
F8
mg
F9
mg
F10
mg
Cefixime 400 400 400 400 400 400 400 400 400 400
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NaHCO3 20 30 40 40 50 50 60 70 70 80
Na alginate 10 20 10 20 20 20 -- 10 --  10
Chitosan 10 -- 10 10 20 20 20 20 25  25
Carbopol 30 25 20 20 20 20 10  10 10  10
MCC 30 30 30 20 20 -- 10  20 10 --
Xanthan gum 10 10 -- -- 10 10 20 -- 20 10
Lactose 40  35 30 30 20  20  20  20 15  15
Adipic Acid 10  10 10 10 10  10  10  10 10  10
Talc 10  20 10 20 -  20  20  10 10 10
Mg stearate 30 30 30 30 30 30  30  30 30  30
Evaluation of post-compressional parameters of tablets
Weight variation:
Twenty tablets were selected at random and weighed individually. The average weight of 20
tablets was calculated.  Individual weights of  the tablets  were compared with the average
weight.
Uniformity of weight:
Table-7 IP Standards for uniformity of weight
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The  values  of  average  weight  are  given  in  above  Table  7 and  are  in within limit
Sr. No Average weight of tablet Percentage of deviation
1 <80mg 10
2 80 – 250 mg 7.5
3 >250mg 5
Hardness:  Tablet  hardness has  been defined as  the force required breaking a tablet  in a
diametric compression test. A tablet was placed between two anvils of hardness tester, force
was  applied  to  the  anvils,  and  the  crushing strength  that  causes  the  tablet  to  break  was
recorded in kg/cm.
Friability: Tablets require certain amount of strength or hardness and resistance to withstand
mechanical  shock of  handling in  manufacturing,  packaging,  and shipping.  A pre-weighed
sample (20 tablets) were placed in the friabilator, and operated for 100 revolutions, then again
weighed the tablets and % friability was calculated using the formula
F = 1 – Wo/ W× 100
Where
Wo=Weight of tablet before test
W= Weight of tablet after test
Drugs content:
To evaluate a tablet potential for efficacy, the amount of drug per tablet needs to be monitored
from tablet to tablet, and batch to batch. To perform the test, 10 tablets were crushed using
mortar pestle.  Quantity equivalent  to 100 mg of drug was dissolved in 100 ml Methanol,
filtered and diluted up to 50µg/ml, and analyze spectrophotometrically at 290.00.nm. The
concentration of drug was determined using standard calibration curve
Buoyancy determination:
The  buoyancy  test  of tablet was studied by placing them in 200 ml beaker containing 0.1 N
HCl,  then tablet  from same batches  were  placed  in  dissolution test  apparatus  containing
900ml 0.1N HCl, maintained at 37±0.5°C and agitated at 50 rpm. The floating onset time
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(time period between placing tablet in the medium and buoyancy beginning) and floating
duration of tablet was determined by visual observation
In-vitro dissolution study:
The in vitro dissolution test was performed using USP type II dissolution test apparatus. The
drug release study was carried out in 0.1 N HCl for 12 hrs in900 ml of dissolution media,
maintained at 37±0.5°C and agitated at 100 rpm. Periodically 5 ml samples were withdrawn
and  filtered  through  Whatman  filter  paper  and  samples  were  replaced  by  its  equivalent
volume  of  dissolution  media.  The  concentration  of  Cefixime  was  measured
spectrophotometrically at 288 nm. Percentage drug release was calculated using an equation
obtained  from  a  standard  curve.  Analysis  of  data  was  done  by  using  ‘PCP Disso  V-3’
software; India.  The graphs of times vs. percentage release were plotted.  To ascertain the
order and mechanism of drug release the in vitro release data was subjected to various kinetic
equations
Treatment of dissolution data with different kinetic equations
To analyze the mechanism of release and release rate kinetics of the dosage form, the data 
obtained were fitted into Zero order, First order, Higuchi matrix, Peppas release model. 
Based on the  r-value, the best-fit model was selected
Zero  order  kinetics:  Drug  dissolution  from  pharmaceutical  dosage  forms  that  do  not
disaggregate and release the drug slowly,  assuming that the area does not change and no
equilibrium conditions are obtained can be represented by the following equation
Qt =Qo Kot
Where
Qt= amount of drug dissolved in time t
Qo = initial amount of the drug in the solution and
K0= zero order release constant
t   = time in hours
It describes the systems where the drug release rate is independent of its concentration of the 
dissolved substance.
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First order kinetics: To study the first order release rate kinetics, the release rate data were 
fitted to the following equation
Log Qt =logQoKot /2.303
Where,
Qt    =the amount of drug released in time t
Qo=the initial amount of drug in the solution
Ko is the first order release constant.
Higuchi model:
Higuchi developed several theoretical models to study the release of water soluble and low 
soluble drugs incorporated in semisolids and/or solid matrices. Mathematical expressions 
were obtained for drug particles dispersed in a uniform matrix behaving as the diffusion 
media. And the equation is,
Q=KHt1/2
Where
Q= cumulative amount of drug release at time “t”
KH =   Higuchi constant
t = time in hours
The Higuchi equation suggests that the drug release by diffusion.
Korsmeyer-peppas method:
Korsmeyer – peppas equation is
      F = (Mt /M) = Kmtn
   Where
                        F   = Fraction of drug released at time‘t’
Mt= Amount of drug released at time‘t’
M = Total amount of drug in dosage form 
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Km= Kinetic constant
 n   = Diffusion or release exponent         
 t    = Time in hours
‘n’ is estimated from linear regression of  log ( Mt/M ) versus log t
If n = 0.45 indicates fickian diffusion
0.45<n<0.89 indicates anomalous diffusion or non-fickian diffusion.
Swelling characteristics (Water uptake study):
The swelling properties of HPMC matrices containing drug were determined by placing the
tablet matrices in the dissolution test apparatus, in 900 ml of distilled water at 37 ± 0.5°C
paddle rotated at 50 rpm. The tablets were removed periodically from dissolution medium.
After draining free from water by blotting paper, these were measured for weight gain. (Table
6)  Swelling characteristics  were expressed in  terms of  percentage water  uptake (WU %)
according to the equation.
% WU = Weight of swollen tablet – initial wt of tablet/ initial wt of tablet × 100
Stability studies:
Short-term stability studies were performed at a temperature of 45°±1°C over a period of
three weeks (21 days) on the promising CGPS tablet formulation F10 Sufficient number of
tablets (10) were packed in amber coloured screw capped bottles and kept in hot air-oven
maintained at 45°±1°C. Samples were taken at weekly intervals for drug content estimation.
At the end of three weeks period, dissolution test and in vitro floating studies were performed
to determine the drug release profiles
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6. RESULTS
                                             
                                             
Table-8 Precompressional data
  
Preformulation  study:  Initially,  procured  raw  materials  were  characterized  for  given
specifications and comply with provided literature value. Physical mixture of cefixime and
polymers were prepared and found to be compatible after evauation.
Melting point: Observed  melting  point  of  cefixime  was  found  in  the  range  of 240 -
242° C, which comply with given literature value.
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Batch
No
Bulk density
(gm/cm3 )
Tapped
density
(gm/cm3 )
Carr’s
Index
(IC )
Hausner
ratio
(HR )
Angle of
repose
F1 0.3432±0.04 0.4165±.05 21.35±0.07 1.21±0.03 24.92±0.08
F2 0.3648±0.06 0.4262±0.03 16.83±0.01 1.16±0.08 29.48±0.10
F3 0.3322±0.04 0.3950±0.04 16.94±0.07 1.18±0.05 25.24±0.17
F4 0.3655±0.05 0.4156±0.06 13.70±0.07 1.13±0.07 26.07±0.18
F5 0.3236±0.01 0.3946±0.01 21.94±0.06 1.21±0.09 22.14±0.14
F6 0.3938±0.06 0.4565±0.07 15.92±0.02 1.15±0.09 28.28±0.11
F7 0.3443±0.04 0.4166±0.04 20.99±0.09 1.20±0.09 30.14±0.13
F8 0.3258±0.06 0.3946±0.04 21.11±0.01 1.21±0.01 24.32±0.15
F9 0.3524±0.05 0.4214±0.08 19.58±0.002 1.19±0.05 21.09±0.12
F10 0.3364±0.06 0.3965±0.12 17.86±0.05 1.17±0.08 24.40±0.15
Results
Evaluations  of  dry  mixed  powder  blend  for precompressional parameters:
The granulation characteristics are the most important interest to formulation scientist and
therefore most universally measured. These basic measurements of the granulation have been
used  to  develop and  monitor  the manufacture of  many successful  pharmaceutical  dosage
forms. Table 4 depicts the powder blend properties of Cefixime floating tablets.
Bulk density may influence compressibility, tablet porosity, dissolution and other properties
and depends on the particle size, shape and tendency of particles to adhere together. The bulk
density of powder blend was found to be between 0.3061 ± 0.04 to 0.3694 ± 0.04 g/cm3
(Table-8). This indicates good packing capacity of powder blend. Carr’s index was evaluated.
Interparticulate cohesive properties with angle of repose measurements and the effects of
packing geometry of  solids with bulk and tapped density were studied. Bulk density and
tapped density measurements found that density of a powder depends on particle packing and
that density changes as the powder consolidates. The degree of consolidation is unique to the
powder and ratio of these densities is related to interparticulate friction. This ratio, percent
compressibility,  was  used  as  an  index  of  flow.  Adhesive/cohesive  forces  of  particles  are
related  to  flow  behaviour.  Values  of  Carr’s  index  below  15%  usually  show  good  flow
characteristics, but readings above 25 % indicate poor flow ability. Carr’s index was found to
be  between  14.89  ± 0.03 to  21.06 ± 0.11.  Hausner’s  ratio  is  simple  method to  evaluate
stability of  powder  column and  to  estimate  flow properties.  Low range was  observed in
Hausner’s ratio that indicates good flowing ability. Many different types of angular properties
have been employed to assess flowing ability. Angle of repose is suited for particles >150µm
 Angle of repose of 30° generally indicate the free flowing material and angle of 40° suggest
a  poor  flowing material.  The  angle  of  repose  is  indicative  of  the  flowing  ability  of  the
material. 
The angle of repose of all the formulations fell within the range of 19.09 ±0.017   to 29.24 ±
0.09   i.e. granules were of good flow properties.
Excipients compatibility study
DIFFERENTIAL SCANNING COLORIMETRY
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Fig-11 Differential scanning colorimetric study of pure drug cefixime
67
Results
Fig-12 Differential scanning colorimetric study of F9
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The floating tablet formulation prepared with Cefixime, chitosan, carbopol, sodium alginate
were subjected for DSC studies, wherein formulation product F3 started melting at 85°C and
completed at 164°C. This wide range of melting process suggests that formulation F9 is a
product of physical mixture of all the constituents mentioned herein, if it is a reaction product
which might have formed during the formulation, it would give rise to short range of melting
process , which has not happened in this case. This confirms the drug used in the formulation
is in the free state rather than in the chemically reacted form. Drug is freely available to the
system whenever administered. Similar observation is made with the formulation F10. In this
case also,  the formulation started melting process,  preceded up to185. One can draw the
conclusion that, during the process of formulation in this case also, drug and constituents
have not undergone any chemical reaction. 
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FTIR study
Fig -13 IR spectra of plain Cefixime Trihydrate
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Fig-14 IR SPECTRA OF F8 FORMULATION
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Fig-15 IR SPECTRA OF F9 FORMULATION
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FTIR study
In  the  present  study  the  drug  Cefixime  is  taken  for  study.   This  molecule  exhibited
characteristic  NH3  absorption peak at  3290 cm which is  a normal  range of  absorption of
primary amines. The NH of the amide group has shown absorption range at 30 to 25 cm and
corresponding the C-H of the aromatic as well as aliphatic functionalities are observed at
3140, 3032, 2978 and 2947 cm. The C=O absorption peak of the carboxylic acid have given
rise  to  an overlapping absorption of  two carboxylic  acids  functional  groups.  C=O of the
amide  both  cyclic  imides  and  amide  are  seen  at  1664  cm  these  observations  are  in
concurrence with the structure of the drug molecule.  The formulation F9 is carried out with
chitosan  and  the  drug  has  given  rise  to  absorption  peaks  at  3298 cm as  a  broad  hump
corresponding to NH, NH and OH functionalities present in the drug as well as polymer
chitosan. Similarly broad peaks are observed at 1700, 1710 and 1600 cm corresponding to the
C=O of the drug and polymer molecules. These data suggests that, the formulated product is
a mixture of drug and the polymer chitosan but not the reaction product. is taken in which
very broad hump is observed at 3420 cm corresponding to the NH the drug and polymer
carbopol. Similar broad peaks are observed 1650 cm corresponding to the C=O of carboxylic
acids and amide moieties present in the both the components. These observations support the
idea  that  formulated  product  is  a  mixture  of  drug  and  the  polymer  but  not  the  reaction
product.  Even  in  case  of  F8,  expected  broad  humps  are  observed  at  3398,  1700  cm
corresponding to the NH, NH2, OH functionalities and COOH, CO functional groups present
in the drug suggesting that, this formulation is not a reaction product but it is a mixture of the
drug and the polymer.
Evaluation of post compressional parameters of tablet characteristics
The  floating  tablets  of  Cefixime  were  prepared  with  direct  compression  technique.  The
tablets were evaluated for average weight, thickness, hardness, friability and drug content.
Tablet thickness, diameter and hardness
All  the formulations were evaluated for various parameters,  like thickness,  diameter  and
hardness of all tablets from batch F1 to F10 are shown in table 9. As there was not  much
variation  in  thickness  of  tablets  in  each  formulation,  it  shows  that  powder  blends  were
consistent in particle size and uniform behaviour during compression process. Thickness and
diameter  of  tablets  of  all  batches  was  measured by vernier  caliper  and there  will  be no
change  in  thickness  and  diameter  of  tablets  respectively.  Thickness  was  in  range  of
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4.20±0.04 to 4.50± 0.04. The hardness of tablet was measured on monsanto hardness tester.
The hardness was in range of 7 to 9 Kg/cm2. Tablet hardness reflects differences in tablet
density and porosity, which are supposed to result in difference release patterns of the drug
by affecting the rate of penetration of the dissolution fluid at the surface of the tablet.
Friability of tablet:
The values of friability are given in table 9. The present study of tablets is within the limit
and the slight variation in friability is because of the variation in compression force applied
and its total weight.   The friability of tablets also depends on type of filler and  moisture
content.
Table-9 Evaluation of post compressional parameters of tablet characteristics
Batch no Average wt
(mg)
Thickness
(mm)
Diameter
(mm)
Hardness
(kg/cm2)
Friability
(%)
F1 596 4.20±0.03 12.1±0.05 7.50±0.01 0.78±0.041
F2 600 4.35±0.04 12.08±0.02 8.40±.02 0.77±0.039
F3 597 4.20±0.02 12.05±0.03 9.0±0.04 0.75±0.044
F4 602 4.4±0.04 12.06±0.02 7.0±0.03 0.66±0.039
F5 600 4.30±0.03 12.01±0.01 7.6±0.05 0.76±0.054
F6 604 4.2±0.04 12.05±0.03 8.3±0.06 0.80±0.066
F7 602 4.23±0.03 12.06±0.04 8.1±0.07 0.72±0.042
F8 602 4.33±0.04 12.08±0.02 7.4±0.02 0.81±0.044
F9 601 4.45±0.04 12.07±0.01 7.0±0.03 0.70±0.065
F10 604 4.50±0.04 12.2±0.02 8.8±0.04 0.66±0.039
DRUG CONTENT AND SWELLING INDEX STUDY
Drug  content  was  in  range  of  96.38  ±  0.12  to  106.44  ±  0.12  indicating good  content
uniformity in  all formulations. That indicates drug was uniformly distributed throughout the
tablet.
Swelling index: 
Results of water uptake study showed that  the order of swelling in these polymers could
indicate the rates at which the preparations are able to absorb water and swell. Maximum
liquid  uptake  and  swelling  of  polymer  was  achieved up  to  12  hrs  and  then  gradually
decreased due to erosion.
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       The swelling of  polymers  used  in  this  CGPS tablets  (Chitosan,  carbopol,  sodium
alginate) could be determined by water uptake of the tablets
Table-10 Drug Content and Swelling Index Study
The complete swelling was achieved by the end of 12 hrs. The % of swelling of F10 was
higher due to increase in the concentration of carbopol which also gives the firm structure to
the tablet form.
BATCH NO Drug content (%) Swelling index
F1 101.18±0.13 68.42±0.80
F2 108.63±0.12 96.56±0.56
F3 102.71±0.22 34.26±0.23
F4 104.91±0.15 51.68±0.14
F5 102.36±0.14 78.40±0.20
F6 104.73±0.13 46.36±0.20
F7 108.68±0.10 98.20±0.45
F8 109.88±0.21 76.40±0.63
F9 101.38±0.20 111.40±0.86
F10 98.68±0.20 86.23±0.23
IN VITRO BUOYANCY AND LAG TIME STUDY
From the results obtained , it was found that formulation F6 did not float. This was due to the
lower percentage of gas generating agent and high concentrations of carbopol polymer. The
formulation F2, F5, F6, F7 floated but the lag time was more and floating time is less. For the
formulations F7, F8, F9 and F10 the duration of buoyancy was more than 12 hrs, the floating
capacity  increased  in  these  formulations  and  floated  with  less  lag  time  due  to  high
concentration of gas generating agent. It was observed that paddle speed affected the floating
properties of tablet. In the study with 200 ml 0.1N HCL without paddle it was found that the
floating lag time decreased and the duration increased for the same formulations.
It was seen that as carbopol 934P concentration decreased, the floating capacity increased.
F9  floated  with  less  lag time due  to  high  concentration  of  gas  generating  agent.  It  was
observed that paddle speed affected the floating properties of tablet However, some results
revealed that, as the concentration 0f chitosan increased, total floating time increased, this is
because  of  increased  gel  strength  of  matrices,  which  prevents  escape  of  evolved  carbon
dioxide  from  matrices,  leading  to  decreased  density  of  the  formulations  In  the  present
invention,  it  has  found that  a  xanthan  gum helps  in maintaining  tablet  integrity.  As  the
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amount of polymer in the tablet formulation increases, the drug release rate decreases and as
the concentration of gas generating agent (NaHCO3) increases the drug release increases and
at the same time floating lags time decreases.
Fig-16 In vitro Buoyancy Study
AFTER 1MIN                             AFTER 1HOUR                    AFTER 12 HOURS
Table-11 Floating ability of various CGPS cefixime tablet formulation
BATCH NO Floating Lag time (min) Floating duration (min)
Integrity
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F1 48 60
F2 60 60
F3 34 480
F4 12 180
F5 10 360
F6 Not floating Not floating
F7 5 >720
F8 4 >720
F9 4 >720
F10 3 >720
In-vitro release study of CGPS floating tablets of Cefixime:
 In-vitro release data of all the formulations were given in table 8.at the end of 6hrs and 12
hrs. The releases of Cefixime from all the formulations were in the range of 38.48 ± 5.34 to
68.18 ± 1.34 at the end of 6 hr and 54.52 ± 0.69 to 97.35 ± 1.09 at the end of 12 hrs. The
formulations  F1,  F2,  F3  and  F4  which  are  prepared  by  using  11%  to  15%  sodium
bicarbonate, mcc 4% to 10%, xanthan gum 5% to 10%, sodium Alginate 5% to 15%, chitosan
5% to 10%, released the drug 66.85 at the end of 12 hrs respectively. The detailed in vitro
data were plotted for percentage drug released Vs time The formulations F5, F6, F7, F8 and
F9 which are prepared by using 10 to15% sodium bicarbonate, xanthan gum 5% to 10%,
sodium alginate 5% to 15%, carbopol 2% to 10%, chitosan 10% to 15% and citric acid 5%
released the drug 96.35 at the end of 12 hrs respectively. The detailed data were plotted for
percentage drug released Vs time as shown in fig12.
From the dissolution study it was concluded that release from the matrix is largely dependent
on the polymer swelling, drug diffusion and matrix erosion. The drug release study is carried
out up to 12 hrs.  The percentage drug release from batch F1 to F10 vary from 54.52 to
97.35%.  The results were revealed that as concentration of sodium bicarbonate increases
from 50 - 80 mg/tab there is decrease in drug release but lag time decreases as increase in
concentration  of  sodium  bicarbonate  and  duration  of  floating  has  been  increased  with
increase in concentration of sodium bicarbonate
Large concentration of high viscosity polymer induces the formation of strong viscous gel
layer that slowed down the rate of water diffusion into the tablet matrix, which may result in
the retardation or decreases the drug release. Being water soluble polymers, they dissolve and
form pores filled liquid in which drug can there after diffuse in dissolution medium. All the
formulations were designed as dosage forms for 12 hrs. The results suggest that therapeutic
levels of Cefixime can be delivered in the controlled manner. It may be concluded that, the
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CGPS Cefixime tablet formulations F6, F8 and F9 show promising controlled drug release. In
other  studied  the  effect  gas  generating  agent  on  In-vitro  release  of  drug  from  floating
formulation revealed that, as the concentration of sodium bicarbonate increases from 60 to 80
mg/tablet,  drug  release  decrease,  this  might  be  because  sodium  bicarbonate  creates  an
alkaline environment around the tablet.  Formulation containing 60mg sodium bicarbonate
showed maximum release when compared to formulation containing 70 mg and 80 mg of
sodium bicarbonate shows less drug release at the end of 24 hrs.
Table-12 In-vitro % drug release data at the end of 12 hrs from CGPS
BATCH
NO
1 hr 2hrs 4hrs 6hrs 8hrs 10hrs 12hrs
F1 7.8±0.6 13.5±0.91 21.88±1.6 35.5±0.8 42.64±0.9 50.93±1.2 62.43±0.23
F2 8.62±0.69 19.25±0.4 29.42±2 40.68±0.9 60.01±1.2 75.28±0.9 80.93±0.2
F3 6.48±0.3 12,26±0.4 25.68±0.5 37.48±3 47.67±2 52.68±4 68.45±0.4
F4 8.96±0.5 15.64±0.6 27.32±0.7 39.86±0.3 56.23±0.7 67.38±0.6 86.85±0.8
F5 7.36±0.2 18.78±0.5 32.68±0.53 43.64±0.6 59.42±0.7 70.42±0.8 83.46±0.6
F6 10.36±0.5 21.68±0.45 36.42±0.3 52.48±0.7 68.68±0.4 84.68±0.8 90.48±1
F7 9.46±0.4 19.88±0.3 31.62±0.2 46.48±0.5 62.32±0.2 79.78±0.6 88.64±0.7
F8 11.43±0.6 23.46±0.5 38.46±0.4 56.54±0.5 72.33±0.4 85.42±0.3 93.51±1
F9 10.48±0.5 28.48±0.6 42.38±0.4 62.26±0.6 83.46±0.7 94.64±0.8 96.35±0.9
F10 11.24±0.2 24.54±0.3 40.44±O.5 59.36±0.6 78.48±0.5 82.36±0.9 84.62±1.2
Fig -17 Percent Drug Released Vs Time Plots of formulations F 1 to F5
78
Results
0 2 4 6 8 10 12 14
0
10
20
30
40
50
60
70
80
90
100
F1 F2 F3 F4 F5
TIME IN HOURS
%
 
DR
UG
 
R
EL
EA
SE
Fig-18 Percent Drug Released Vs Time Plots of formulations F5 to F10
0 2 4 6 8 10 12 14
0
20
40
60
80
100
120
F6 F7 F8 F9 F10
TIME IN HOURS
%
 D
R
U
G
 R
E
L
E
A
S
E
Curve fitting analysis for different formulations
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The kinetic data of CGPS Cefixime tablets
The correlation coefficient r values of zero order of all the formulations were in the range of
0.9357  to  0.9823  and  first  order  r  values  were  from  0.9397  to0.9816.   Among  the  10
formulations some formulations (F3, F5, F6,) release the drug by first order kinetics and
some (F1, F2, F4, F7, F8, F9, F10,) release by zero order kinetics.
The results suggest that, the drug was released by mixed order kinetics to ascertain, the drug
release mechanism the in-vitro release data were also subjected to Higuchi’s diffusion plots
and Peppas plots and the correlation coefficient values were in the range of 0.971 to 0.979
and 0.913 to 0.918 respectively. So it confirms that , the calculated r values for Higuchi plot
and Peppas plots were nearer to  one (1) in all the cases suggesting that drug released by
diffusion mechanism
 The mean diffusional exponent values (n) ranged from 0.55  to 0.66 indicating that all these
formulations presented a dissolution behaviour controlled by Non Fickian Diffusion (When n
tends towards< 0.5)
Table-13 Dissolution kinetics
Batch No Zero order First order Higuchi’s Peppa’s
F1 0.997 0.985 0.971 0.913
F2 0.994 0.983 0.965 0.908
F3 0.995 0.984 0.968 0.918
F4 0.997 0.972 0.954 0.900
F5 0.997 0.988 0.975 0.903
F6 0.994 0.991 0.969 0.907
F7 0.997 0.994 0.967 0.890
F8 0.992 0.994 0.980 0.871
F9 0.981 0.995 0.978 0.923
F10 0.972 0.995 0.979 0.875
Fig-19 Cumulative percent release Vs Time (Zero order) of Formulations F1, F2, F3, F4,
and F5
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Fig-20 Cumulative percent release Vs Time (Zero order) of Formulations F6, F7, F8, F9
and F10
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Fig-21 Cumulative percent release Vs Time (First order) of Formulations F1, F2, F3, F4
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Fig-22 Cumulative percent release Vs Time (First order) of FormulationsF6, F7, F8, F9
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Fig-23 Cumulative percentage release Vs Square root of Time (Higuchi plot) of
Formulations F1, F2, F3, F4, and F5
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Fig-24 Cumulative percentage release Vs Square root of Time (Higuchi plot) of
FormulationsF6, F7, F8, F9 and F10
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Fig-25 Log Cumulative percent release Vs Log Time (peppa’s plot) of Formulations F1,
F2, F3, F4 and F5
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Fig-26 Log Cumulative percentage drug release Vs Log Time (peppa’s plots) of
FormulationsF6, F7, F8, F9 and F10
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Stability studies
Short-term stability studies  were performed at  a temperature of  45° ± 1°C over a
period of three weeks (21 days) on the promising CGPS tablet formulation F9. Sufficient
number of tablets (15) were packed in amber coloured screw capped bottles and kept in hot
air-oven maintained at 45° ± 1°C. Samples were taken at weekly intervals for drug content
estimation.  At  the  end  of  three  weeks  period,  dissolution  test  and  floating  studies  were
performed to determine the drug release profiles, the estimation of drug contents and data of
Table-14 In-vitro release data of stability study of formulation F9
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SL.NO
TIME
(hrs)
% cumulative drug release
1st Day 21stDay
1 1 10.48 9.41
2 2 28.48 26.98
3 3 36.54 35.13
4 4 42.38 40.48
5 5 58.21 57.27
6 6 62.26 61.39
7 7 72.56 73.46
8 8 83.46 82.87
9 9 89.23 88.73
10 10 94.64 92.78
11 11 95.81 94.21
12 12 96.35 95.60
Summary and Conclusion
7. SUMMARY
According to the obtained results, the floating tablets of Cefixime include a swelling agent
and a gel forming polymer. Together these agents form a hydrated gel matrix. The tablet
further contains a gas  generating component such that a gas is generated in a controlled
manner and is entrapped in hydrated gel matrix. The swelling agent which belongs to class of
super disintegrants absorbs large amount of fluid and causes matrix significantly. However, in
the present  invention,   swelling   of   matrix   is   controlled   by  the   viscolyzing   agent
(carbopol), which acts both as swellability and a release controlling agent. The gas generating
component sodium bicarbonate interacts with an acid source citric acid  by contact with
gastric fluid to generate carbon dioxide. In the present invention,  it has found that a
carbopol helps in maintaining tablet integrity, when stirred in aqueous medium.
The  floating tablet  formulations  are  evaluated  for  different  precompressional  and  post
compressional  parameters  the  results  revealed  that  the  all  formulations  shows  good
precompressional properties showing better flowability, hardness is maintained in the range
of  5  to  7kg/cm2 which  provides  good  mechanical  strength  to the CGPS tablet. Other
parameters like weight variation, friability, thickness,  drug  content  are  in  the  range  of
prescribed limits of IP.
The in vitro drug release results suggest that, the drug was released by mixed order kinetics.
To  ascertain,  the drug release mechanism the  in-vitro release data were also subjected to
Higuchi’s diffusion and Peppa, s plots by taking log percent versus log time. Results of
these kinetic plots and n values, suggest that the drug was released by Non-Fickian control
(Anomalous diffusion) with swelling. In the present study floating controlled drug delivery
systems of Cefixime were successfully developed in the form of tablets to improve the local
action and its bioavailability, which reduces the wastage of drug and ultimately improves the
solubility for drugs that are less soluble in high pH environment.
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Summary and Conclusion
CONCLUSION
From the above experimental results it  can be concluded that, Formulated floating
tablets gave satisfactory  results  for  various  post  compressional  parameters like hardness,
friability,  thickness, weight variation and content  uniformity.   Sodium bicarbonate has
predominant effect on the buoyancy lag time, while Chitosan, has predominant effect on
total floating time and drug release. Carbopol also shows significant effect on drug release.
Sodium alginate and Xanthan gum has given extra adhesion property and helped to maintain
the integrity of the tablet.  Floating matrix tablet with good floating and a controlled release
pattern.   Swelling index has a significant effect on the drug release.  The formulations F8
and  F9  showed  higher swelling index  compared  to  others.   In-vitro  release  rate  studies
showed that the maximum drug release was observed in F8 and F9 formulations up to 12 hrs.
Formulations F9 found to be stable at 45oC and 75% RH for a period of 21 days.  FT-IR
studies revealed that there was no interaction between Cefixime and  the polymers  used.
From the study it is evident that a promising gas powered controlled release floating
tablets  of  Cefixime can be developed to increase gastric  residence  time  and  thereby
increasing  its  bioavailability.  Further  detailed  investigations are required to establish
efficacy of these formulations and fix the required dose.
.
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